U.S. patent application number 17/574884 was filed with the patent office on 2022-05-05 for anti-hcmv compositions and methods.
This patent application is currently assigned to Evrys Bio, LLC. The applicant listed for this patent is Evrys Bio, LLC. Invention is credited to Lillian Chiang, Emre Koyuncu, Stacy Remiszewski, Qun Sun.
Application Number | 20220135556 17/574884 |
Document ID | / |
Family ID | |
Filed Date | 2022-05-05 |
United States Patent
Application |
20220135556 |
Kind Code |
A1 |
Remiszewski; Stacy ; et
al. |
May 5, 2022 |
ANTI-HCMV COMPOSITIONS AND METHODS
Abstract
Novel compounds useful for treating and/or preventing HCMV
infections are provided.
Inventors: |
Remiszewski; Stacy;
(Doylestown, PA) ; Koyuncu; Emre; (Doylestown,
PA) ; Sun; Qun; (Princeton, NJ) ; Chiang;
Lillian; (Princeton, NJ) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
Evrys Bio, LLC |
Doylestown |
PA |
US |
|
|
Assignee: |
Evrys Bio, LLC
Doylestown
PA
|
Appl. No.: |
17/574884 |
Filed: |
January 13, 2022 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
16724343 |
Dec 22, 2019 |
|
|
|
17574884 |
|
|
|
|
15525504 |
May 9, 2017 |
10556894 |
|
|
PCT/US2015/059746 |
Nov 9, 2015 |
|
|
|
16724343 |
|
|
|
|
62077804 |
Nov 10, 2014 |
|
|
|
International
Class: |
C07D 417/14 20060101
C07D417/14; A61K 31/427 20060101 A61K031/427; C07D 417/04 20060101
C07D417/04; C07D 491/052 20060101 C07D491/052; C07D 417/06 20060101
C07D417/06; C07D 417/10 20060101 C07D417/10; A61K 45/06 20060101
A61K045/06; A61K 31/436 20060101 A61K031/436; A61K 31/4725 20060101
A61K031/4725; A61K 31/498 20060101 A61K031/498; A61K 31/5377
20060101 A61K031/5377; A61K 31/506 20060101 A61K031/506; A61K
31/4709 20060101 A61K031/4709 |
Goverment Interests
STATEMENT OF FEDERALLY FUNDED RESEARCH
[0001] The U.S. Government has a paid-up license in this invention
and the right, in limited circumstances, to require the patent
owner to license others on reasonable terms as provided for in the
terms of grant number 1R43AI110048-01 awarded by the National
Institute of Allergy and Infections Diseases.
Claims
1. A composition comprising a compound of Formula I: ##STR00117##
wherein: Ar is ##STR00118## wherein each cyclic 5- or 6-membered
ring in Ar optionally contains up to two N heteroatoms, Y is,
independently in each instance, CH.sub.2 or a bond, Ring B is
selected from the group consisting of: ##STR00119## m is 0, 1 or 2,
n is, independently in each instance, 0 or 1, p is 0 or 1, when p
is 0, Z.sub.1 is C, when p is 1, Z.sub.1 is C, O, S or NR.sub.7
R.sub.1 is H, halo, --CN, --NO.sub.2, --C(O)NR.sub.6R.sub.7, or
C(O)OR.sub.6, R.sub.2 is H or a lower straight or branched alkyl or
alkenyl optionally substituted with one heteroatom selected of N
and O, R.sub.3 is H or OH, R.sub.4 is H or a saturated 5- or
6-membered aryl or cycloalkyl with up to two heteroatoms selected
from N, O and S, R.sub.5 is H, --OR.sub.7, or --NR.sub.6R.sub.7,
R.sub.6 and R.sub.7 are independently selected in each instance
from H and lower straight chain or branched alkyl, when Ring A is
aromatic, X.sub.5 is C or N, when Ring A is not aromatic, X.sub.5
is C, O, S or NR.sub.7, when m=0 or 1, Z.sub.2 is C, and when m=2,
Z.sub.2 is C, O, S or NR.sub.7; or a pharmaceutically acceptable
salt thereof, with the proviso that the compound is not:
##STR00120## or a pharmaceutically acceptable salt thereof.
2. (canceled)
3. (canceled)
4. (canceled)
5. The composition of claim 1, comprising a compound of Formula V
or a pharmaceutically acceptable salt thereof: ##STR00121## wherein
X.sub.1 and X.sub.2 are independently selected from C and N.
6. (canceled)
7. (canceled)
8. The composition of claim 5, wherein R.sub.4 is in the meta or
para position and is selected from the group consisting of pyrrole,
imidazole, pyrazole, pyrazine, pyrimidine and pyridazine.
9. The composition of claim 5, wherein the compound is selected
from the group consisting of: ##STR00122## and pharmaceutically
acceptable salts thereof.
10. (canceled)
11. (canceled)
12. (canceled)
13. (canceled)
14. (canceled)
15. (canceled)
16. (canceled)
17. (canceled)
18. (canceled)
19. (canceled)
20. (canceled)
21. (canceled)
22. (canceled)
23. (canceled)
24. (canceled)
25. (canceled)
26. (canceled)
27. (canceled)
28. (canceled)
29. (canceled)
30. (canceled)
31. (canceled)
32. (canceled)
33. (canceled)
34. (canceled)
35. (canceled)
36. (canceled)
37. (canceled)
38. (canceled)
Description
TECHNICAL FIELD
[0002] This document relates to compounds useful for preventing,
treating or ameliorating human cytomegalovirus infection.
BACKGROUND
[0003] Human cytomegalovirus (HCMV) is a major cause of birth
defects and opportunistic infections in immunosuppressed
individuals, and a possible cofactor in certain cancers. Organ
transplant patients under immunosuppressive therapy are at high
risk for viral infections; activation of a latent virus as well as
donor or community acquired primary infections can cause
significant complications including graft rejection, morbidity, and
mortality. Herpesviruses (e.g. HCMV, HSV-1), polyomaviruses (e.g.
BKV and JCV), hepatitis viruses (HBV and HCV) and respiratory
viruses (e.g. influenza A, adenovirus) are the 4 major viral
classes infecting these patients. Cytomegalovirus (HCMV) is the
most prevalent post-transplant pathogen; HCMV can infect most
organs, and despite the availability of HCMV antivirals such as
ganciclovir, nephrotoxic side effects and increasing rates of
drug-resistance significantly reduce graft and patient survival. In
addition, HCMV-mediated immune modulation can reactivate distinct
latent viruses carried by most adults.
SUMMARY
[0004] The invention provides compounds having the structure of
Formula I:
##STR00001## [0005] wherein: [0006] Ar is
[0006] ##STR00002## [0007] wherein each cyclic 5- or 6-membered
ring in Ar optionally contains up to two N heteroatoms, [0008] Y
is, independently in each instance, C or a bond, [0009] Ring B is
selected from the group consisting of:
[0009] ##STR00003## [0010] m is 0, 1 or 2, [0011] n is,
independently in each instance, 0 or 1, [0012] p is 0 or 1, [0013]
when p is 0, Z.sub.1 is C, [0014] when p is 1, Z.sub.1 is C, O, S
or NR.sub.7 [0015] R.sub.1 is H, halo, --CN, --NO.sub.2,
--C(O)NR.sub.6R.sub.7, or C(O)OR.sub.6, [0016] R.sub.2 is H or a
lower straight or branched alkyl or alkenyl optionally substituted
with one heteroatom selected of N and O, [0017] R.sub.3 is H or OH,
[0018] R.sub.4 is H or a saturated 5- or 6-membered aryl or
cycloalkyl with up to two heteroatoms selected from N, O and S,
[0019] R.sub.5 is H, --OR.sub.7, or --NR.sub.6R.sub.7, [0020]
R.sub.6 and R.sub.7 are independently selected in each instance
from H and lower straight chain or branched alkyl, [0021] when Ring
A is aromatic, X.sub.5 is C or N, [0022] when Ring A is not
aromatic, X.sub.5 is C, O, S or NR.sub.7, [0023] when m=0 or 1,
Z.sub.2 is C, and [0024] when m=2, Z.sub.2 is C, O, S or NR.sub.7;
The compounds of the invention are useful for treating and/or
preventing HCMV infections.
[0025] The invention also provides methods of preventing, treating
and/or ameliorating HCMV infections with compounds of Formula
I.
[0026] Unless otherwise defined, all technical and scientific terms
used herein have the same meaning as commonly understood by one of
ordinary skill in the art to which this invention belongs. Methods
and materials are described herein for use in the present
invention; other, suitable methods and materials known in the art
can also be used. The materials, methods, and examples are
illustrative only and not intended to be limiting. All
publications, patent applications, patents, sequences, database
entries, and other references mentioned herein are incorporated by
reference in their entirety. In case of conflict, the present
specification, including definitions, will control.
[0027] Other features and advantages of the invention will be
apparent from the following detailed description and FIGURES, and
from the claims.
DETAILED DESCRIPTION
[0028] Provided herein are compounds useful in the treatment and/or
prevention of HCMV infections.
[0029] Provided herein are methods for treating or preventing a
HCMV infection in a subject. In some embodiments, the methods
include administering a therapeutically effective amount of one or
more of the compounds provided herein. In some embodiments, the
compounds provided herein can inhibit HCMV production in a cell
infected with the virus. In such embodiments, the cell is contacted
with a virus production inhibiting amount of one or more compounds
provided herein.
[0030] Provided herein are compounds of the structure of Formula
I:
##STR00004## [0031] wherein: [0032] Ar is
[0032] ##STR00005## [0033] wherein each cyclic 5- or 6-membered
ring in Ar optionally contains up to two N heteroatoms, [0034] Y
is, independently in each instance, C or a bond, [0035] Ring B is
selected from the group consisting of:
[0035] ##STR00006## [0036] m is 0, 1 or 2, [0037] n is,
independently in each instance, 0 or 1, [0038] p is 0 or 1, [0039]
when p is 0, Z.sub.1 is C, [0040] when p is 1, Z.sub.1 is C, O, S
or NR.sub.7 [0041] R.sub.1 is H, halo, --CN, --NO.sub.2,
--C(O)NR.sub.6R.sub.7, or C(O)OR.sub.6, [0042] R.sub.2 is H or a
lower straight or branched alkyl or alkenyl optionally substituted
with one heteroatom selected of N and O, [0043] R.sub.3 is H or OH,
[0044] R.sub.4 is H or a saturated 5- or 6-membered aryl or
cycloalkyl with up to two heteroatoms selected from N, O and S,
[0045] R.sub.5 is H, --OR.sub.7, or --NR.sub.6R.sub.7, [0046]
R.sub.6 and R.sub.7 are independently selected in each instance
from H and lower straight chain or branched alkyl, [0047] when Ring
A is aromatic, X.sub.5 is C or N, [0048] when Ring A is not
aromatic, X.sub.5 is C, O, S or NR.sub.7, [0049] when m=0 or 1,
Z.sub.2 is C, and [0050] when m=2, Z.sub.2 is C, O, S or NR.sub.7;
or a pharmaceutically acceptable salt thereof, with the proviso
that the compound is not:
##STR00007##
[0050] or a pharmaceutically acceptable salt thereof. The compounds
of Formula I are useful for preventing, treating and/or
ameliorating a HCMV infection.
[0051] Some embodiments of the of the anti-HCMV compounds provided
herein have the structure of Formula II,
##STR00008##
[0052] wherein X.sub.1, X.sub.2, X.sub.3 and X.sub.4 are
independently selected from C and N and all the other variables are
as defined for Formula I,
[0053] or a pharmaceutically acceptable salt thereof, with the
proviso that the compound is not
##STR00009##
or a pharmaceutically acceptable salt thereof.
[0054] Some embodiments of the of the anti-HCMV compounds provided
herein have the structure of Formula III,
##STR00010##
[0055] wherein X.sub.1, X.sub.2, X.sub.3 and X.sub.4 are
independently selected from C and N and all the other variables are
as defined for Formula I,
[0056] or a pharmaceutically acceptable salt thereof.
Some embodiments of the of the anti-HCMV compounds provided herein
have the structure of Formula IV,
##STR00011##
[0057] wherein X.sub.1, X.sub.2, X.sub.3 and X.sub.4 are
independently selected from C and N and all other variables are as
defined for Formula I,
[0058] or a pharmaceutically acceptable salt thereof.
Some embodiments of the of the anti-HCMV compounds provided herein
have the structure of Formula V,
##STR00012##
[0059] wherein X.sub.1 and X.sub.2 are independently selected from
C and N and all other variables are as defined in Formula I,
[0060] or a pharmaceutically acceptable salt thereof.
Some embodiments of the of the anti-HCMV compounds provided herein
have the structure of Formula VI,
##STR00013##
[0061] wherein X.sub.1 and X.sub.2 are independently selected from
C and N and all other variables are as defined for Formula I,
[0062] or a pharmaceutically acceptable salt thereof.
[0063] Some embodiments of the of the anti-HCMV compounds provided
herein have the structure of Formula VII, The composition of claim
1, comprising a compound of Formula VII or a pharmaceutically
acceptable salt thereof:
##STR00014##
[0064] wherein X.sub.1 and X.sub.2 are independently selected from
C and N, and all other variables are defined as in Formula I,
[0065] or a pharmaceutically acceptable salt thereof.
[0066] In some embodiments of the compounds of Formulas V, VI and
VII, R.sub.4 is in the meta or para position and is selected from
the group consisting of pyrrole, imidazole, pyrazole, pyrazine,
pyrimidine and pyridazine.
[0067] In some embodiments of the compounds of Formulas I, II, III,
V, VI and VII, R.sub.1, if present in the formula, is H, halo,
--CN, or --NO.sub.2, and R.sub.4, if present in the formula, is a
saturated 5- or 6-membered aryl or cycloalkyl with up to two
heteroatoms selected from N, O and S.
[0068] In some embodiments of the compounds of Formula I, the
compound is selected from the group consisting of:
##STR00015## ##STR00016##
[0069] and pharmaceutically acceptable salts thereof.
[0070] Some embodiments of the method for treating or preventing a
HCMV infection in a subject provided herein can include
administering a therapeutically effective amount of a compound of
Formula I, Formula II, Formula III, Formula IV, Formula V, Formula
VI, Formula VII or pharmaceutically acceptable salts thereof.
[0071] Also provided herein is a method of inhibiting HCMV
production comprising contacting a HCMV-infected cell with a virus
production inhibiting amount of any of the compounds of Formulas I,
II, III, IV, V, VI and VII.
[0072] An antiviral agent can also be administered in conjunction
with the compounds and the methods described herein. The agent can
be any therapeutic agent useful in the treatment of a HCMV
infection. For example, an antiviral agent can include acyclovir,
docosanol, ribarivin, interferons, and the like; cellulose acetate,
carbopol and carrageenan, pleconaril, amantidine, rimantidine,
fomivirsen, zidovudine, lamivudine, zanamivir, oseltamivir,
brivudine, abacavir, adefovir, amprenavir, arbidol, atazanavir,
atripla, cidofovir, combivir, edoxudine, efavirenz, emtricitabine,
enfuvirtide, entecavir, famciclovir, fosamprenavir, foscarnet,
fosfonet, ganciclovir, gardasil, ibacitabine, imunovir,
idoxuridine, imiquimod, indinavir, inosine, integrase inhibitor,
lamivudine, lopinavir, loviride, mk-0518, maraviroc, moroxydine,
nelfinavir, nevirapine, nexavir, nucleotide and/or nucleoside
analogues, oseltamivir, penciclovir, peramivir, podophyllotoxin,
rimantadine, ritonavir, saquinavir, stavudine, tenofovir, tenofovir
disoproxil, tipranavir, trifluridine, trizivir, tromantadine,
truvada, valaciclovir, valganciclovir, vicriviroc, vidarabine,
viramidine, zalcitabine, morpholino oligonucleotides, ribozyme,
protease inhibitors, an assembly inhibitor (e.g., rifampicin),
zidovudine, brincidofovir, favipiravir, nitoxanide, letermovir,
maribavir, CMX157 or a combination or two or more antiviral
agents.
[0073] In some embodiments, a compound provided herein can be
administered before, after, or simultaneously with the
administration or one or more antiviral agents.
[0074] A compound provided herein, including a pharmaceutically
acceptable salt thereof, can be purchased commercially or prepared
using known organic synthesis techniques.
[0075] The methods provided herein include the manufacture and use
of pharmaceutical compositions, which include compounds provided
herein and one or more pharmaceutically acceptable carriers. Also
provided herein are the compositions themselves.
[0076] Pharmaceutical compositions typically include a
pharmaceutically acceptable carrier. As used herein the language
"pharmaceutically acceptable carrier" includes saline, solvents,
dispersion media, coatings, antibacterial and antifungal agents,
isotonic and absorption delaying agents, and the like, compatible
with pharmaceutical administration.
[0077] A pharmaceutical composition is typically formulated to be
compatible with its intended route of administration. Examples of
routes of administration include parenteral, e.g., intravenous,
intradermal, subcutaneous, oral (e.g., inhalation), transdermal
(topical), transmucosal, and rectal administration.
[0078] Methods of formulating suitable pharmaceutical compositions
are known in the art, see, e.g., Remington: The Science and
Practice of Pharmacy, 21st ed., 2005; and the books in the series
Drugs and the Pharmaceutical Sciences: a Series of Textbooks and
Monographs (Dekker, N.Y.). For example, solutions or suspensions
used for parenteral, intradermal, or subcutaneous application can
include the following components: a sterile diluent such as water
for injection, saline solution, fixed oils, polyethylene glycols,
glycerine, propylene glycol, or other synthetic solvents;
antibacterial agents such as benzyl alcohol or methyl parabens;
antioxidants such as ascorbic acid or sodium bisulfite; chelating
agents such as ethylenediaminetetraacetic acid; buffers such as
acetates, citrates, or phosphates and agents for the adjustment of
tonicity such as sodium chloride or dextrose. pH can be adjusted
with acids or bases, such as hydrochloric acid or sodium hydroxide.
The parenteral preparation can be enclosed in ampoules, disposable
syringes, or multiple dose vials made of glass or plastic.
[0079] Pharmaceutical compositions suitable for injection can
include sterile aqueous solutions (where water soluble) or
dispersions and sterile powders for the extemporaneous preparation
of sterile injectable solutions or dispersions. For intravenous
administration, suitable carriers include physiological saline,
bacteriostatic water, Cremophor EL.TM. (BASF, Parsippany, N.J.) or
phosphate buffered saline (PBS). In all cases, the composition must
be sterile and should be fluid to the extent that easy
syringability exists. The composition should be stable under the
conditions of manufacture and storage and must be preserved against
the contaminating action of microorganisms such as bacteria and
fungi. The carrier can be a solvent or dispersion medium
containing, for example, water, ethanol, polyol (for example,
glycerol, propylene glycol, liquid polyethylene glycol, and the
like), and suitable mixtures thereof. The proper fluidity can be
maintained, for example, by the use of a coating such as lecithin,
by the maintenance of the required particle size in the case of
dispersion and by the use of surfactants. Prevention of the action
of microorganisms can be achieved by various antibacterial and
antifungal agents, for example, parabens, chlorobutanol, phenol,
ascorbic acid, thimerosal, and the like. In many cases, it will be
preferable to include isotonic agents, for example, sugars,
polyalcohols such as mannitol, sorbitol, and sodium chloride in the
composition. Prolonged absorption of the injectable compositions
can be brought about by including in the composition an agent that
delays absorption, for example, aluminum monostearate and
gelatin.
[0080] Sterile injectable solutions can be prepared by
incorporating a compound provided herein in the required amount in
an appropriate solvent with one or a combination of ingredients
enumerated above, as required, followed by filtered sterilization.
Generally, dispersions are prepared by incorporating a compound
provided herein into a sterile vehicle, which contains a basic
dispersion medium and the required other ingredients from those
enumerated above. In the case of sterile powders for the
preparation of sterile injectable solutions, the preferred methods
of preparation are vacuum drying and freeze-drying, which yield a
powder of a compound provided herein plus any additional desired
ingredient from a previously sterile-filtered solution thereof.
[0081] Oral compositions generally include an inert diluent or an
edible carrier. For the purpose of oral therapeutic administration,
a compound provided herein can be incorporated with excipients and
used in the form of tablets, troches, or capsules, e.g., gelatin
capsules. Oral compositions can also be prepared using a fluid
carrier for use as a mouthwash. Pharmaceutically compatible binding
agents, and/or adjuvant materials can be included as part of the
composition. The tablets, pills, capsules, troches and the like can
contain any of the following ingredients, or compounds of a similar
nature: a binder such as microcrystalline cellulose, gum tragacanth
or gelatin; an excipient such as starch or lactose, a
disintegrating agent such as alginic acid, Primogel, or corn
starch; a lubricant such as magnesium stearate or Sterotes; a
glidant such as colloidal silicon dioxide; a sweetening agent such
as sucrose or saccharin; or a flavoring agent such as peppermint,
methyl salicylate, or orange flavoring.
[0082] For administration by inhalation, the compounds can be
delivered in the form of an aerosol spray from a pressured
container or dispenser that contains a suitable propellant, e.g., a
gas such as carbon dioxide, or a nebulizer. Such methods include
those described in U.S. Pat. No. 6,468,798.
[0083] Systemic administration of a therapeutic compound as
described herein can also be by transmucosal or transdermal means.
For transmucosal or transdermal administration, penetrants
appropriate to the barrier to be permeated are used in the
formulation. Such penetrants are generally known in the art, and
include, for example, for transmucosal administration, detergents,
bile salts, and fusidic acid derivatives. Transmucosal
administration can be accomplished through the use of nasal sprays
or suppositories. For transdermal administration, the compounds
provided herein can be formulated into ointments, salves, gels, or
creams as generally known in the art.
[0084] The pharmaceutical compositions can also be prepared in the
form of suppositories (e.g., with conventional suppository bases
such as cocoa butter and other glycerides) or retention enemas for
rectal delivery.
[0085] Additionally, intranasal delivery is possible, as described
in, inter alia, Hamajima et al., Clin. Immunol. Immunopathol.,
88(2), 205-10 (1998). Liposomes (e.g., as described in U.S. Pat.
No. 6,472,375) and microencapsulation can also be used.
Biodegradable targetable microparticle delivery systems can also be
used (e.g., as described in U.S. Pat. No. 6,471,996).
[0086] In one embodiment, the therapeutic compounds are prepared
with carriers that will protect the therapeutic compounds against
rapid elimination from the body, such as a controlled release
formulation, including implants and microencapsulated delivery
systems. Biodegradable, biocompatible polymers can be used, such as
ethylene vinyl acetate, polyanhydrides, polyglycolic acid,
collagen, polyorthoesters, and polylactic acid. Such formulations
can be prepared using standard techniques, or obtained
commercially, e.g., from Alza Corporation and Nova Pharmaceuticals,
Inc. Liposomal suspensions (including liposomes targeted to
selected cells with monoclonal antibodies to cellular antigens) can
also be used as pharmaceutically acceptable carriers. These can be
prepared according to methods known to those skilled in the art,
for example, as described in U.S. Pat. No. 4,522,811.
[0087] The pharmaceutical composition may be administered at once,
or may be divided into a number of smaller doses to be administered
at intervals of time. It is understood that the precise dosage and
duration of treatment is a function of the disease being treated
and may be determined empirically using known testing protocols or
by extrapolation from in vivo or in vitro test data. It is to be
noted that concentrations and dosage values may also vary with the
severity of the condition to be alleviated. It is to be further
understood that for any particular patient, specific dosage
regimens should be adjusted over time according to the individual
need and the professional judgment of the person administering or
supervising the administration of the compositions, and that the
concentration ranges set forth herein are exemplary only and are
not intended to limit the scope or practice of the claimed
compositions.
[0088] Dosage forms or compositions containing a compound as
described herein in the range of 0.005% to 100% with the balance
made up from non-toxic carrier may be prepared. Methods for
preparation of these compositions are known to those skilled in the
art. The contemplated compositions may contain 0.001%400% of a
compound provided herein, in one embodiment 0.1-95%, in another
embodiment 75-85%.
[0089] The pharmaceutical compositions can be included in a
container, pack, or dispenser together with instructions for
administration.
[0090] As described above, the preparations of one or more
compounds provided herein may be given orally, parenterally,
topically, or rectally. They are, of course, given by forms
suitable for each administration route. For example, they are
administered in tablets or capsule form, by injection, inhalation,
eye lotion, ointment, suppository, infusion; topically by lotion or
ointment; and rectally by suppositories. In some embodiments,
administration is oral.
[0091] The phrases "parenteral administration" and "administered
parenterally" as used herein means modes of administration other
than enteral and topical administration, usually by injection, and
includes, without limitation, intravenous, intramuscular,
intraarterial, intrathecal, intracapsular, intraorbital,
intracardiac, intradermal, intraperitoneal, transtracheal,
subcutaneous, subcuticular, intraarticular, subcapsular,
subarachnoid, intraspinal and intrasternal injection, and
infusion.
[0092] Actual dosage levels of the active ingredients in the
pharmaceutical compositions provided herein may be varied so as to
obtain an amount of the active ingredient which is effective to
achieve the desired therapeutic response for a particular patient,
composition, and mode of administration, without being toxic to the
patient.
[0093] The concentration of a compound provided herein in a
pharmaceutically acceptable mixture will vary depending on several
factors, including the dosage of the compound to be administered,
the pharmacokinetic characteristics of the compound(s) employed,
and the route of administration. In some embodiments, the
compositions provided herein can be provided in an aqueous solution
containing about 0.1-10% w/v of a compound disclosed herein, among
other substances, for parenteral administration. Typical dose
ranges can include from about 0.01 to about 50 mg/kg of body weight
per day, given in 1-4 divided doses. Each divided dose may contain
the same or different compounds. The dosage will be a
therapeutically effective amount depending on several factors
including the overall health of a patient, and the formulation and
route of administration of the selected compound(s).
[0094] Although the dosage will vary depending on the symptoms, age
and body weight of the patient, the nature and severity of the
disorder to be treated or prevented, the route of administration
and the form of the drug, in general, a daily dosage of from 0.01
to 2000 mg of the compound is recommended for an adult human
patient, and this may be administered in a single dose or in
divided doses. The amount of active ingredient which can be
combined with a carrier material to produce a single dosage form
will generally be that amount of the compound which produces a
therapeutic effect.
[0095] The precise time of administration and/or amount of the
composition that will yield the most effective results in terms of
efficacy of treatment in a given patient will depend upon the
activity, pharmacokinetics, and bioavailability of a particular
compound, physiological condition of the patient (including age,
sex, disease type and stage, general physical condition,
responsiveness to a given dosage, and type of medication), route of
administration, etc. However, the above guidelines can be used as
the basis for fine-tuning the treatment, e.g., determining the
optimum time and/or amount of administration, which will require no
more than routine experimentation consisting of monitoring the
patient and adjusting the dosage and/or timing.
[0096] Also provided herein is a conjoint therapy wherein one or
more other therapeutic agents are administered with a compound or a
pharmaceutical composition comprising a compound provided herein.
Such conjoint treatment may be achieved by way of the simultaneous,
sequential, or separate dosing of the individual components of the
treatment.
Definitions
[0097] For the terms "for example" and "such as," and grammatical
equivalences thereof, the phrase "and without limitation" is
understood to follow unless explicitly stated otherwise. As used
herein, the term "about" is meant to account for variations due to
experimental error. All measurements reported herein are understood
to be modified by the term "about", whether or not the term is
explicitly used, unless explicitly stated otherwise. As used
herein, the singular forms "a," "an," and "the" include plural
referents unless the context clearly dictates otherwise.
[0098] A "subject," as used herein, includes both humans and other
animals, particularly mammals. Thus, the methods are applicable to
both human therapy and veterinary applications. In some
embodiments, the patient is a mammal, for example, a primate. In
some embodiments, the patient is a human.
[0099] A "therapeutically effective" amount of a compound provided
herein is typically one which is sufficient to prevent, eliminate,
ameliorate or reduce the symptoms of a HCMV infection. It will be
appreciated that different concentrations may be employed for
prophylaxis than for treatment of an active disease.
[0100] A "virus production inhibiting" amount of a compound
provided herein is typically one which is sufficient to achieve a
measurable reduction in the amount of virus produced by the cells
contacted with the compound. In some embodiments, a "virus
production inhibiting" amount is an amount which inhibits a least
30% of the virus production in untreated cells. In some
embodiments, a "virus production inhibiting" amount is an amount
which inhibits a least 50% of the virus production in untreated
cells. In some embodiments, a "virus production inhibiting" amount
is an amount which inhibits a least 70% of the virus production in
untreated cells. In some embodiments, a "virus production
inhibiting" amount is an amount which inhibits a least 90% of the
virus production in untreated cells.
[0101] The terms "treatment" and "prevention" are art-recognized
and include administration of one or more of the compounds or
pharmaceutical compositions provided herein. If it is administered
prior to clinical manifestation of the unwanted condition (e.g.,
disease or other unwanted state of the subject) then the treatment
is preventative, (i.e., it protects the subject against developing
the unwanted condition). As used in this context, the term
"prevent" means to slow or prevent the onset of at least one
symptom of a disorder as provided herein. For example, such
prevention may be prompted by a likelihood of exposure to an
infective agent (e.g., a virus) or when a subject exhibits other
symptoms that indicate onset of a disorder (e.g., a metabolic
disorder or cardiovascular disorder) may be likely. Alternatively,
if it is administered after manifestation of the unwanted
condition, the treatment is therapeutic, (i.e., it is intended to
diminish, ameliorate, or stabilize the existing unwanted condition
or side effects thereof). As used in this context, to "treat" means
to ameliorate at least one symptom of a disorder as provided
herein.
[0102] The term, "compound," as used herein is meant to include all
stereoisomers, geometric isomers, and tautomers of the structures
depicted. Compounds herein identified by name or structure as one
particular tautomeric form are intended to include other tautomeric
forms unless otherwise specified.
[0103] In some embodiments, a compound provided herein, or salt
thereof, is substantially isolated. By "substantially isolated" it
is meant that the compound is at least partially or substantially
separated from the environment in which it was formed or detected.
Partial separation can include, for example, a composition enriched
in the compound provided herein. Substantial separation can include
compositions containing at least about 50%, at least about 60%, at
least about 70%, at least about 80%, at least about 90%, at least
about 95%, at least about 97%, or at least about 99% by weight of
the compound provided herein, or salt thereof. Methods for
isolating compounds and their salts are routine in the art.
[0104] The phrase "pharmaceutically acceptable" is used herein to
refer to those compounds, materials, compositions, and/or dosage
forms which are, within the scope of sound medical judgment,
suitable for use in contact with the tissues of human beings and
animals without excessive toxicity, irritation, allergic response,
or other problem or complication, commensurate with a reasonable
benefit/risk ratio.
[0105] The term "pharmaceutically acceptable salt" refers to the
relatively non-toxic, inorganic and organic acid addition salts of
a compound provided herein. These salts can be prepared in situ
during the final isolation and purification of a compound provided
herein, or by separately reacting the compound in its free base
form with a suitable organic or inorganic acid, and isolating the
salt thus formed. Representative salts include the hydrobromide,
hydrochloride, sulfate, bisulfate, phosphate, nitrate, acetate,
valerate, oleate, palmitate, stearate, laurate, benzoate, lactate,
phosphate, tosylate, citrate, maleate, fumarate, succinate,
tartrate, naphthylate, mesylate, glucoheptonate, lactobionate,
laurylsulphonate salts, and amino acid salts, and the like. (See,
for example, Berge et al. (1977) "Pharmaceutical Salts", J. Pharm.
Sci. 66: 1-19.)
[0106] In some embodiments, a compound provided herein may contain
one or more acidic functional groups and, thus, is capable of
forming pharmaceutically acceptable salts with pharmaceutically
acceptable bases. The term "pharmaceutically acceptable salts" in
these instances refers to the relatively non-toxic inorganic and
organic base addition salts of a compound provided herein. These
salts can likewise be prepared in situ during the final isolation
and purification of the compound, or by separately reacting the
purified compound in its free acid form with a suitable base, such
as the hydroxide, carbonate, or bicarbonate of a pharmaceutically
acceptable metal cation, with ammonia, or with a pharmaceutically
acceptable organic primary, secondary, or tertiary amine.
Representative alkali or alkaline earth salts include the lithium,
sodium, potassium, calcium, magnesium, and aluminum salts, and the
like. Representative organic amines useful for the formation of
base addition salts include ethylamine, diethylamine,
ethylenediamine, ethanolamine, diethanolamine, piperazine, and the
like (see, for example, Berge et al., supra).
[0107] The term "alkyl" as employed herein refers to straight and
branched chain aliphatic groups having from 1 to 12 carbon atoms,
preferably 1-8 carbon atoms, and more preferably 1-6 carbon atoms,
which is optionally substituted with one, two or three
substituents. Preferred alkyl groups include, without limitation,
methyl, ethyl, propyl, isopropyl, butyl, isobutyl, secbutyl,
tertbutyl, pentyl, and hexyl. A "C.sub.0" alkyl (as in
"C.sub.0-C.sub.3-alkyl") is a covalent bond (like "C.sub.0"
hydrocarbyl). The term "lower alkyl" refers to straight and
branched chain aliphatic groups having from 1 to 6 carbon atoms.
Unless otherwise specified, the term "alkyl" includes alkenyl,
alkynyl and cyclic alkyl groups.
[0108] The term "alkenyl" as used herein means an unsaturated
straight or branched chain aliphatic group with one or more
carbon-carbon double bonds, having from 2 to 12 carbon atoms,
preferably 2-8 carbon atoms, and more preferably 2-6 carbon atoms,
which is optionally substituted with one, two or three
substituents. Preferred alkenyl groups include, without limitation,
ethenyl, propenyl, butenyl, pentenyl, and hexenyl.
[0109] The term "alkynyl" as used herein means an unsaturated
straight or branched chain aliphatic group with one or more
carbon-carbon triple bonds, having from 2 to 12 carbon atoms,
preferably 2-8 carbon atoms, and more preferably 2-6 carbon atoms,
which is optionally substituted with one, two or three
substituents. Preferred alkynyl groups include, without limitation,
ethynyl, propynyl, butynyl, pentynyl, and hexynyl.
[0110] The term "heteroalkyl" refers to an alkyl group, as defined
herein above, wherein one or more carbon atoms in the chain are
replaced by a heteroatom selected from the group consisting of O,
S, and N.
[0111] An "aryl" group is a C.sub.6-C.sub.14 aromatic moiety
comprising one to three aromatic rings, which is optionally
substituted. Preferably, the aryl group is a C.sub.6-C.sub.10 aryl
group. Preferred aryl groups include, without limitation, phenyl,
naphthyl, anthracenyl, and fluorenyl.
[0112] A "heterocyclyl" or "heterocyclic" group is a ring structure
having from about 3 to about 8 atoms, wherein one or more atoms are
selected from the group consisting of N, O, and S. The heterocyclic
group is optionally substituted on carbon at one or more positions.
The heterocyclic group is also independently optionally substituted
on nitrogen with alkyl, aryl, aralkyl, alkylcarbonyl, alkyl
sulfonyl, arylcarbonyl, aryl sulfonyl, alkoxycarbonyl,
aralkoxycarbonyl, or on sulfur with oxo or lower alkyl. Preferred
heterocyclic groups include, without limitation, epoxy, aziridinyl,
tetrahydrofuranyl, pyrrolidinyl, piperidinyl, piperazinyl,
thiazolidinyl, oxazolidinyl, oxazolidinonyl, and morpholino. In
certain preferred embodiments, the heterocyclic group is fused to
an aryl, heteroaryl, or cycloalkyl group. Examples of such fused
heterocycles include, without limitation, tetrahydroquinoline and
dihydrobenzofuran. Specifically excluded from the scope of this
term are compounds having adjacent annular O and/or S atoms.
[0113] As used herein, the term "heteroaryl" refers to groups
having 5 to 14 ring atoms, preferably 5, 6, 9, or 10 ring atoms;
having 6, 10, or 14 .pi. electrons shared in a cyclic array; and
having, in addition to carbon atoms, from one to three heteroatoms
per ring selected from the group consisting of N, O, and S. A
"heteroaralkyl" or "heteroarylalkyl" group comprises a heteroaryl
group covalently linked to an alkyl group, either of which is
independently optionally substituted or unsubstituted. Preferred
heteroalkyl groups comprise a C1-C6 alkyl group and a heteroaryl
group having 5, 6, 9, or 10 ring atoms. Specifically excluded from
the scope of this term are compounds having adjacent annular O
and/or S atoms. Examples of preferred heteroaralkyl groups include
pyridylmethyl, pyridylethyl, pyrrolylmethyl, pyrrolylethyl,
imidazolylmethyl, imidazolylethyl, thiazolylmethyl, and
thiazolylethyl. Specifically excluded from the scope of this term
are compounds having adjacent annular O and/or S atoms.
[0114] Embodiments of heterocyclyls and heteroaryls include, but
are not limited to, acridinyl, azocinyl, benzimidazolyl,
benzofuranyl, benzothiofuranyl, benzothiophenyl, benzoxazolyl,
benzthiazolyl, benztriazolyl, benztetrazolyl, benzisoxazolyl,
benzisothiazolyl, benzimidazolinyl, carbazolyl, 4aH-carbazolyl,
carbolinyl, chromanyl, chromenyl, cinnolinyl, decahydroquinolinyl,
2H,6H-1,5,2-dithiazinyl, dihydrofuro[2,3b]tetrahydrofuran, furanyl,
furazanyl, imidazolidinyl, imidazolinyl, imidazolyl, 1H-indazolyl,
indolenyl, indolinyl, indolizinyl, indolyl, 3H-indolyl,
isobenzofuranyl, isochromanyl, isoindazolyl, isoindolinyl,
isoindolyl, isoquinolinyl, isothiazolyl, isoxazolyl,
methylenedioxyphenyl, morpholinyl, naphthyridinyl,
octahydroisoquinolinyl, oxadiazolyl, 1,2,3-oxadiazolyl,
1,2,4-oxadiazolyl, 1,2,5-oxadiazolyl, 1,3,4-oxadiazolyl,
oxazolidinyl, oxazolyl, oxazolidinyl, pyrimidinyl, phenanthridinyl,
phenanthrolinyl, phenazinyl, phenothiazinyl, phenoxathiinyl,
phenoxazinyl, phthalazinyl, piperazinyl, piperidinyl, piperidonyl,
4-piperidonyl, piperonyl, pteridinyl, purinyl, pyranyl, pyrazinyl,
pyrazolidinyl, pyrazolinyl, pyrazolyl, pyridazinyl, pyridooxazole,
pyridoimidazole, pyridothiazole, pyridinyl, pyridyl, pyrimidinyl,
pyrrolidinyl, pyrrolinyl, 2H-pyrrolyl, pyrrolyl, quinazolinyl,
quinolinyl, 4H-quinolizinyl, quinoxalinyl, quinuclidinyl,
tetrahydrofuranyl, tetrahydroisoquinolinyl, tetrahydroquinolinyl,
tetrazolyl, 6H-1,2,5-thiadiazinyl, 1,2,3-thiadiazolyl,
1,2,4-thiadiazolyl, 1,2,5-thiadiazolyl, 1,3,4-thiadiazolyl,
thianthrenyl, thiazolyl, thienyl, thienothiazolyl, thienooxazolyl,
thienoimidazolyl, thiophenyl, triazinyl, 1,2,3-triazolyl,
1,2,4-triazolyl, 1,2,5-triazolyl, 1,3,4-triazolyl, and
xanthenyl.
[0115] As employed herein, when a moiety (e.g., cycloalkyl,
hydrocarbyl, aryl, heteroaryl, heterocyclic, urea, etc.) is
described as "optionally substituted" it is meant that the group
optionally has from one to four, preferably from one to three, more
preferably one or two, non-hydrogen substituents. Suitable
substituents include, without limitation, halo, hydroxy, oxo (e.g.,
an annular --CH-- substituted with oxo is --C(O)--), nitro,
halohydrocarbyl, hydrocarbyl, aryl, aralkyl, alkoxy, aryloxy,
amino, acylamino, alkylcarbamoyl, arylcarbamoyl, aminoalkyl, acyl,
carboxy, hydroxyalkyl, alkanesulfonyl, arenesulfonyl,
alkanesulfonamido, arenesulfonamido, aralkylsulfonamido,
alkylcarbonyl, acyloxy, cyano, and ureido groups.
[0116] The term "halogen" or "halo" as employed herein refers to
chlorine, bromine, fluorine, or iodine. As herein employed, the
term "acyl" refers to an alkylcarbonyl or arylcarbonyl substituent.
The term "acylamino" refers to an amide group attached at the
nitrogen atom (i.e., R--CO--NH--). The term "carbamoyl" refers to
an amide group attached at the carbonyl carbon atom (i.e.,
NH.sub.2--CO--). The nitrogen atom of an acylamino or carbamoyl
substituent is optionally additionally substituted. The term
"sulfonamido" refers to a sulfonamide substituent attached by
either the sulfur or the nitrogen atom. The term "amino" is meant
to include NH.sub.2, alkylamino, arylamino, and cyclic amino
groups. The term "ureido" as employed herein refers to a
substituted or unsubstituted urea moiety.
[0117] A moiety that is substituted is one in which one or more
hydrogens have been independently replaced with another chemical
substituent. As a non-limiting example, substituted phenyls include
2-flurophenyl, 3,4-dichlorophenyl, 3-chloro-4-fluoro-phenyl,
2-fluor-3-propylphenyl. As another non-limiting example,
substituted n-octyls include 2,4 dimethyl-5-ethyl-octyl and
3-cyclopentyl-octyl. Included within this definition are methylenes
(--CH.sub.2--) substituted with oxygen to form carbonyl-CO--).
[0118] An "unsubstituted" moiety as defined above (e.g.,
unsubstituted cycloalkyl, unsubstituted heteroaryl, etc.) means
that moiety as defined above that does not have any of the optional
substituents for which the definition of the moiety (above)
otherwise provides. Thus, for example, while an "aryl" includes
phenyl and phenyl substituted with a halo, "unsubstituted aryl"
does not include phenyl substituted with a halo.
Synthesis of Compounds of the Invention
[0119] The compounds in the present invention (compounds of general
Formula I) can be prepared using the general reaction scheme set
out in the schemes below.
##STR00017##
[0120] A suitable compound of general formula 1 where R.sub.1 is H,
a lower straight or branched alkyl or a suitable leaving group,
e.g.,
##STR00018##
can be reacted with 2-chloro-1,3-thiazole and a base, e.g., n-BuLi
or sec-BuLi to afford compounds of general structure 3. Compounds
of general structure 3 can be treated with a suitable reducing
agent, e.g., a silane such as triethylsilane and an acid such as
trifluoroacetic acid to provide compounds of general structure 4.
Compounds of general structure 4 can be treated with a suitable
amine, e.g., benzylamine or 1,2,3,4-tetrahydroisoquinoline to
afford compounds of general structure 5. It will be recognized that
compounds of general structure 5 are identical to compounds of
Formula I where R.sub.3 is H.
[0121] Those skilled in the art will recognize there may be
alternate synthetic paths to provide compounds of Formula I. The
following Schemes describe non-limiting examples of such alternate
synthetic paths.
##STR00019##
[0122] In some instances, compounds of general formula 3 can be
treated with a suitable amine, e.g., benzylamine or
1,2,3,4-tetrahydroisoquinoline to afford compounds of general
structure 6. Compounds of general structure 6 can be treated with a
suitable reducing agent, e.g., a silane such as triethylsilane and
an acid such as trifluoroacetic acid to provide compounds of
general structure 5. It will be recognized that compounds of
general structure 6 are identical to compounds of Formula I where
R.sub.3 is OH.
##STR00020##
[0123] In some instances, where R.sub.1 is a suitable leaving group
as described above for Scheme 1, compounds of general formula 1 can
be reacted with 2-chloro-1,3-thiazole and a base, e.g., n-BuLi or
sec-BuLi to afford compounds of general structure 7. Compounds of
general structure 7 can be treated with a suitable amine as
described above for Schemes 1 and 2 to provide compounds of general
structure 8. Compounds of general structure 8 can be treated with a
suitable reducing agent, e.g., NaBH.sub.4 or LiAlH.sub.4 to afford
compounds of general formula 6 where R.sub.1.dbd.H. Compounds of
general formula 6 can be treated as described above to provide
compound of general formula 5.
##STR00021##
[0124] In some instances, compounds of general formula 6 can be
treated with a suitable acid in the presence or absence of a
co-reagent to provide compounds of general formula 7. Suitable
acids can be organic, e.g., trifluoroacetic acid, or mineral, e.g.,
HCl or H.sub.2SO.sub.4. A co-reagent can be a silane, e.g.,
triethylsilane. Compound of general structure 7 can be reduced
using suitable conditions, e.g., H.sub.2 in the presence of a
suitable catalyst, e.g., Pd/C or Pd(OH).sub.2/C. It will be
recognized that compounds of general structure 7 are identical to
compounds of Formula I where R.sub.2 is alkenyl. It will be
recognized that compounds of general structure 8 are identical to
compounds of Formula I where R.sub.2 is lower straight chain or
branched alkyl.
##STR00022##
[0125] In some instances, compounds of general formula 3 can be
treated with a suitable acid in the presence or absence of a
co-reagent to afford compounds of general formula 9 as described
above for the preparation of compounds of general structure 7
illustrated in Scheme 4. Compounds of general structure 9 can be
treated with a suitable amine as described above for Schemes 1 and
2 to provide compounds of general structure 7; general structure 7
in Scheme 5 is identical to general structure 7 in Scheme 4.
[0126] Methods to perform the above described reactions and
processes would be apparent to those of ordinary skill in the art
based on the present disclosure, or can be deduced in analogy from
the examples. Starting materials are commercially available or can
be made by methods analogous to those described in the Examples
below.
EXAMPLES
[0127] The invention is further described in the following
examples, which do not limit the scope of the invention described
in the claims.
Synthesis of Examples 1, 2 and 3:
##STR00023##
[0129] Procedure: [0130] 1. To a solution of Compound 1 (3 g, 17.2
mmol) in DCM (80 mL) were added N,O-dimethylhydroxylamine
hydrochloride (2.0 g, 20.7 mmol), EDCI (4.0 g, 20.7 mmol), HOBt
(2.3 g, 17.2 mmol) and DIEA (3.7 mL, 20.7 mmol). The resulting
solution was stirred at room temperature (RT) overnight. The
residue was treated with water and extracted with DCM. The organic
extracts were washed with brine, dried over anhydrous
Na.sub.2SO.sub.4, filtered and concentrated to give a crude oil.
The crude product was purified by silica gel chromatography to
afford Compound 2 (2.3 g, 61.5%). [0131] 2. To a solution of
Compound 2 (1 g, 4.6 mmol) in dry THF (10 mL) at 0.degree. C. under
N.sub.2 was added MeMgBr (2 mL, 3.0 mol/L, 6 mmol) dropwise. The
resulting solution was slowly warm to RT over 2 hours. The mixture
was diluted with NH.sub.4Cl solution and extracted with EA. The
organic extracts were concentrated to give a crude oil. The crude
product was purified by silica gel chromatography to afford
Compound 3 (600 mg, 75.7%). [0132] 3. To a solution of
2-chlorothiazole (1 g, 8.4 mmol) in dry THF (10 mL) at -78.degree.
C. under N.sub.2 was added n-BuLi (3.5 mL, 9.2 mmol) dropwise and
the mixture stirred for 1 h. A solution of Compound 3 (1.3 g, 7.6
mmol) in dry THF (5 mL) was added dropwise to the reaction mixture
at -78.degree. C. The resulting solution was slowly warm to RT. The
reaction was diluted with NH.sub.4Cl solution and extracted with
EA. The organic extracts were concentrated to give a crude oil. The
crude product was purified by silica gel chromatography to afford
Example 1 (55 mg, 2%) and Compound 4 (1.6 g, 76.2%).
[0133] Example 1: .sup.1H NMR (CDCl.sub.3, 300 MHz) .delta.:
2.0-2.2 (s, 3H), 4.1-4.2 (s, 1H), 7.3-7.4 (s, 1H), 7.8-7.9 (d, 1H),
8.0-8.1 (d, 1H), 8.2-8.3 (s, 1H), 8.8 (m, 1H), 9.0 (s, 1H), 9.3-9.4
(m, 1H).
[0134] LC-MS: m/z=375.1 (M+1).sup.+. [0135] 4. To a solution of
Compound 4 (800 mg, 2.7 mmol) in DMF (5 mL) were added
1,2,3,4-tetrahydroisoquinoline (550 mg, 4.1 mmol)) and
K.sub.2CO.sub.3 (570 mg, 4.1 mmol). The reaction mixture was
stirred at 80.degree. C. overnight. After cooling to RT, the
residue was treated with water and extracted with EA. The organic
extracts were washed with water, brine, dried over anhydrous
Na.sub.2SO.sub.4, filtered and concentrated to give a crude oil.
The crude product was purified by silica gel chromatography to
afford Example 2 (250 mg, 23.41%).
[0136] LC-MS: m/z=389.2 (M+1).sup.+. [0137] 5. To a solution of
Example 2 (200 mg, 0.51 mmol) in DCE (10 mL) was added TES-H (180
mg, 1.5 mmol), the mixture cooled to 0.degree. C. and TFA (590 mg,
5.1 mmol) was added dropwise. The resulting solution was stirred at
60.degree. C. for 4 hours. The residue was concentrated and
purified by silica gel chromatography to afford Compound 5 (5 mg,
2.6%) and Example 3 (10 mg, 7.1%).
[0138] Example 3: LC-MS: m/z=371.2 (M+1).sup.+.
[0139] Compound 5: LC-MS: m/z=373.2 (M+1).sup.+.
Synthesis of Examples 4-6:
##STR00024##
[0141] Procedure: [0142] 1. A mixture of compound 1 (1.8 g, 10.3
mmol), DIEA (2.7 g, 20.7 mmol), N,O-dimethylhydroxylamine
hydrochloride (1.2 g, 12.4 mmol), EDCI (2.4 g, 12.4 mmol) and HOBT
(1.4 g, 10.3 mmol) in DCM was stirred at RT overnight, water was
added and the mixture extracted with DCM. The combined extracts
were concentrated and the residue purified by column chromatography
to give 1.9 g of compound 2 [0143] 2. To a solution of
2-chlorothiazole (485 mg, 4.05 mmol) in dry THF (10 mL) at
-78.degree. C. under N.sub.2 was added n-BuLi (1.6 mL, 4.05 mmol)
dropwise. After 1 hour a solution of Compound 2 (800 mg, 3.7 mmol)
was added dropwise. The resulting solution was slowly warm to RT.
The reaction was diluted with NH.sub.4Cl solution and extracted
with EA. The organic extracts were concentrated to give a crude
oil. The crude product was purified by silica gel chromatography to
afford Compound 3 (500 mg) [0144] 3. To a solution of Compound 3
(200 mg, 0.73 mmol) in DMF (10 mL) were added
1,2,3,4-tetrahydroisoquinoline (145 mg, 1.09 mmol)) and
K.sub.2CO.sub.3 (200 mg, 1.45 mmol). The reaction mixture was
stirred at 80.degree. C. overnight. After cooling to RT, the
residue was treated with water and extracted with EA. The organic
extracts were washed with water, brine, dried over anhydrous
Na.sub.2SO.sub.4, filtered and concentrated to give a crude oil.
The crude product was purified by silica gel chromatography to
afford Example 6 (300 mg). [0145] 4. To a solution of Example 6
(200 mg, 0.538 mmol) in MeOH, NaBH.sub.4 (50 mg, 1.23 mmol) was
added at RT and the mixture stirred for 2 h. The mixture was
diluted with water and extracted with EA. The extracts were dried
over anhydrous Na.sub.2SO.sub.4, filtered and concentrated to give
150 mg of Example 5. [0146] 5. To a solution of Example 5 (150 mg,
0.4 mmol) in DCE (20 mL) was added TES-H (56 mg, 0.48 mmol), the
mixture cooled to 0.degree. C. and TFA (3.7 g, 32.8 mmol) was added
dropwise at 0.degree. C. The resulting solution was stirred at
60.degree. C. for 4 hours. The residue was concentrated and
purified by silica gel chromatography to afford Example 4 (80
mg).
[0147] .sup.1HNMR (CDCl.sub.3, 300 MHz) .delta.: 1.6-1.7 (d, 2H),
3.0-3.1 (t, 2H), 3.7-3.8 (t, 2H), 4.2-4.3 (m, 1H), 4.6-4.7 (s, 2H),
6.4-6.5 (s, 1H), 7.0-7.1 (s, 1H), 7.2-7.4 (m, 4H), 7.4-7.5 (d, 2H),
7.6-7.8 (m, 3H), 7.9-8.0 (s, 1H).
[0148] LC-MS: m/z=359 (M+1).sup.+.
Synthesis of Example 7:
##STR00025##
[0150] Procedure: [0151] 1. To a solution of 2-chlorothiazole (2.2
g, 18.3 mmol) in dry THF (10 mL) was added n-BuLi (7.5 mL, 18.3
mmol) dropwise at -78.degree. C. under N.sub.2 and the mixture
stirred for 1 h. A solution of Compound 1 (2 g, 16.7 mmol) was
added dropwise at -78.degree. C. The resulting solution was slowly
warmed to RT. The reaction was diluted with NH.sub.4Cl solution and
extracted with EA. The organic extracts were concentrated to give a
crude oil. The crude product was purified by silica gel
chromatography to afford Compound 2 (2 g). [0152] 2. To a solution
of Compound 2 (1 g, 3.28 mmol) in DCE (20 mL) was added TES-H (1.1
g, 9.8 mmol), the mixture cooled to 0.degree. C. and TFA (3.7 g,
32.8 mmol) was added dropwise. The resulting solution was stirred
at 60.degree. C. for 4 hours. The residue was concentrated and
purified by silica gel chromatography to afford Compound 3 (800
mg). [0153] 3. To a solution of Compound 3 (400 mg, 1.4 mmol) in
DMF (10 mL) were added 1,2,3,4-tetrahydroisoquinoline (280 mg, 2.1
mmol)) and K.sub.2CO.sub.3 (390 mg, 2.8 mmol). The reaction mixture
was stirred at 80.degree. C. overnight. After cooling to RT, the
residue was treated with water and extracted with EA. The organic
extracts were washed with water, brine, dried over anhydrous
Na.sub.2SO.sub.4, filtered and concentrated to give a crude oil.
The crude product was purified by silica gel chromatography to
afford Compound 4 (150 mg). [0154] 4. To a solution of Compound 4
(150 mg, 0.4 mmol) in MeOH (10 mL) was added Pd/C (20 mg). The
reaction mixture was stirred at RT under a H.sub.2 balloon
overnight. The residue was filtered, the filter cake washed with
MeOH and the filtrate was concentrated and purified by silica gel
chromatography to afford Example 7 (40 mg).
[0155] .sup.1HNMR (CDCl.sub.3, 300 MHz) .delta.: 1.6-1.7 (d, 2H),
3.0-3.1 (t, 2H), 3.7-3.8 (t, 2H), 4.2-4.3 (m, 1H), 4.6-4.7 (s, 2H),
6.4-6.5 (s, 1H), 7.0-7.1 (s, 1H), 7.2-7.4 (m, 4H), 7.4-7.5 (d, 2H),
7.6-7.8 (m, 3H), 7.9-8.0 (s, 1H).
[0156] LC-MS: m/z=321 (M+1)+.
Synthesis of Example 8:
##STR00026##
[0158] Procedure: [0159] 1. To a solution of 2-chlorothiazole (4.8
g, 48 mmol) in dry THF (50 mL) was added n-BuLi (16 mL, 48 mmol)
dropwise at -78.degree. C. under N.sub.2 and the mixture stirred
for 1 h. A solution of Compound 1 (4 g, 44 mmol) was added dropwise
at -78.degree. C. The resulting solution was slowly warmed to RT.
The reaction was diluted with NH.sub.4Cl solution and extracted
with EA. The organic extracts were concentrated to give a crude
oil. The crude product was purified by silica gel chromatography to
afford Compound 2 (2.1 g). [0160] 2. To a solution of Compound 2
(2.4 g, 10 mmol) in DMF (10 mL) were added
1,2,3,4-tetrahydroisoquinoline (2.6 g, 20 mmol)) and
K.sub.2CO.sub.3 (5.2 mg, 30 mmol). The reaction mixture was stirred
at 80.degree. C. overnight. After cooling to RT, the residue was
treated with water and extracted with EA. The organic extracts were
washed with water, brine, dried over anhydrous Na.sub.2SO.sub.4,
filtered and concentrated to give a crude oil. The crude product
was purified by silica gel chromatography to afford Compound 3 (800
mg). [0161] 3. To a solution of Compound 3 (0.8 g, 2.2 mmol) in DCE
(20 mL) was added TES-H (1.22 g, 4.4 mmol), the mixture cooled to
0.degree. C. and TFA (3 g, 22 mmol) was added dropwise at 0.degree.
C. The resulting solution was stirred at 60.degree. C. for 4 hours.
The residue was concentrated and purified by silica gel
chromatography to afford Compound 4 (100 mg). [0162] 4. To a
solution of Compound 4 (100 mg, 0.3 mmol) in MeOH (10 mL) was added
Pd/C (10 mg). The reaction mixture was stirred at RTunder a H.sub.2
balloon overnight. The residue was filtered, the filter cake was
washed with MeOH and the filtrate was concentrated and purified by
silica gel chromatography to afford Example 8 (36 mg).
[0163] .sup.1H NMR (CDCl.sub.3, 300 MHz) .delta.: 1.6-1.7 (d, 3H),
2.9-3.0 (t, 2H) 3.7-3.8 (t, 2H), 4.2-4.3 (t, 1H), 4.6-4.7 (s, 2H),
6.9-7.0 (s, 1H), 7.1-7.3 (m, 4H), 7.4-7.5 (d, 1H), 8.5-8.6 (m, 2H).
LC-MS: m/z=322 (M+1).sup.+.
Synthesis of Example 9:
##STR00027##
[0165] Procedure: [0166] 1. To a solution of Compound 1 (8 g, 0.05
mmol) in DCM (100 mL) was added Boc.sub.2O (12 g, 1.1 eq), DMAP
(0.5 g 0.1 eq) was added and the mixture was stirred at RT for 2
hours. Water was added and the solution was extracted with DCM. The
organic extracts were washed with brine, dried over
Na.sub.2SO.sub.4, concentrated and the residue purified by
preparative chromatography to give 12 g product of Compound 2.
[0167] 2. To a solution of 2-chlorothiazole (1.6 g, 12 mmol) in dry
THF (30 mL) was added n-BuLi (5.2 mL, 12 mmol) dropwise at
-78.degree. C. under N.sub.2 and the mixture stirred for 1 h. A
solution of Compound 2 (3 g, 11 mmol) was added dropwise at
-78.degree. C. The resulting solution slowly warmed to RT. The
reaction was diluted with NH.sub.4Cl solution and extracted with
EA. The organic extracts were concentrated to give a crude oil. The
crude product was purified by silica gel chromatography to afford
Compound 3 (1.5 g). [0168] 3. To a solution of Compound 3 (2 g, 4.3
mmol) in DCE (20 mL) was added TES-H (1.22 g, 8.6 mmol), the
mixture cooled to 0.degree. C. and TFA (6.5 g, 43 mmol) was added
dropwise at 0.degree. C. The resulting solution was stirred at 60 C
for 4 hours. The residue was concentrated and purified by silica
gel chromatography to afford Compound 4 (400 mg). [0169] 4. To a
solution of Compound 4 (400 mg, 1.2 mmol) in DMF (10 mL) were added
1,2,3,4-tetrahydroisoquinoline (250 mg, 2.1 mmol)) and
K.sub.2CO.sub.3 (500 mg, 3.4 mmol). The reaction mixture was
stirred at 80.degree. C. overnight. After cooling to RT, the
residue was treated with water and extracted with EA. The organic
extracts were washed with water, brine, dried over anhydrous
Na.sub.2SO.sub.4, filtered and concentrated to give a crude oil.
The crude product was purified by silica gel chromatography to
afford Example 9 (50 mg).
[0170] .sup.1H NMR (CDCl.sub.3, 300 MHz) .delta.: 1.6-1.7 (d, 3H),
2.9-3.0 (t, 2H), 3.6-3.7 (t, 2H), 4.4-4.5 (m, 3H), 7.0-7.1 (s, 1H),
7.1-7.3 (m, 9H), 7.3-7.4 (d, 1H), 7.6-7.8 (d, 1H), 7.9-8.0 (s,
1H).
[0171] LC-MS: m/z=360 (M+1)+.
Synthesis of Example 10:
##STR00028##
[0173] Procedure: [0174] 1. To a solution of Compound 1 (3 g, 17.2
mmol) in DCM (80 mL) were added N,O-dimethylhydroxylamine
hydrochloride (2.0 g, 20.7 mmol), EDCI (4.0 g, 20.7 mmol), HOBt
(2.3 g, 17.2 mmol) and DIEA (3.7 mL, 20.7 mmol). The resulting
solution was stirred at RT overnight. The residue was treated with
water and extracted with DCM. The organic extracts were washed with
brine, dried over anhydrous Na.sub.2SO.sub.4, filtered and
concentrated to give a crude oil. The crude product was purified by
silica gel chromatography to afford Compound 2 (2.3 g, 61.5%).
[0175] 2. To a solution of Compound 2 (1 g, 4.6 mmol) in dry THF
(10 mL) at 0.degree. C. under N.sub.2 was added MeMgBr (2 mL, 3.0
mol/L, 6 mmol) dropwise. The resulting solution was slowly warmed
to RT over 2 hours. The reaction was diluted with NH.sub.4Cl
solution and extracted with EA. The organic extracts were
concentrated to give a crude oil. The crude product was purified by
silica gel chromatography to afford Compound 3 (600 mg, 75.7%).
[0176] 3. To a solution of 2-chlorothiazole (1 g, 8.4 mmol) in dry
THF (10 mL) was added n-BuLi (3.5 mL, 9.2 mmol) dropwise at
-78.degree. C. under N.sub.2 and the mixture stirred for 1 h. A
solution of Compound 3 (1.3 g, 7.6 mmol) in dry THF (5 mL) was
added dropwise at -78.degree. C. The resulting solution was slowly
warmed to RT. The reaction was diluted with NH.sub.4Cl solution and
extracted with EA. The organic extracts were concentrated to give a
crude oil. The crude product was purified by silica gel
chromatography to afford Compound 4 (1.6 g, 72.6%).
[0177] .sup.1H NMR (CDCl.sub.3, 300 MHz) .delta.: 2.0-2.1 (s, 3H),
4.1-4.2 (s, 1H), 7.3-7.4 (s, 1H), 7.8-7.9 (d, 1H), 8.0-8.1 (d, 1H),
8.3 (s, 1H), 8.8 (s, 2H). [0178] 4. To a solution of Compound 4
(1.2 g, 4.1 mmol) in DCE (30 mL) was added TES-H (1.4 mg, 12.3
mmol), the mixture cooled to 0.degree. C. and Then TFA (4.7 mg, 41
mmol) was added dropwise. The resulting solution was stirred at
60.degree. C. for 4 hours. The residue was concentrated and
purified by silica gel chromatography to afford Compound 5 (0.6 g,
52.8%). [0179] 5. To a solution of Compound 5 (200 mg, 0.74 mmol)
in DMF (5 mL) were added 3-phenylpyrrolidine (160 mg, 1.1 mmol))
and K.sub.2CO.sub.3 (200 mg, 1.48 mmol). The reaction mixture was
stirred at 80.degree. C. overnight. After cooling to RT, the
residue was treated with water and extracted with EA. The organic
extracts were washed with water, brine, dried over anhydrous
Na.sub.2SO.sub.4, filtered and concentrated to give a crude oil.
The crude product was purified by silica gel chromatography to
afford Example 10 (50 mg, 17.8%).
[0180] .sup.1H NMR (CDCl.sub.3, 300 MHz) .delta.: 1.5-1.7 (s, 4H),
2.3 (m, 1H), 2.5-2.6 (m, 1H), 3.6-3.7 (m, 3H), 3.9 (m, 1H), 4.0-4.1
(m, 1H), 7.2-7.4 (m, 5H), 7.9 (s, 1H), 8.1-8.3 (m, 2H), 8.5-8.6 (s,
1H), 8.9-9.0 (s, 2H).
[0181] LC-MS: m/z=387.2 (M+1).sup.+.
Synthesis of Example 11:
##STR00029##
[0183] Procedure: [0184] 1. To a solution of Compound 1 (3 g, 17.2
mmol) in DCM (80 mL) were added N,O-dimethylhydroxylamine
hydrochloride (2.0 g, 20.7 mmol), EDCI (4.0 g, 20.7 mmol), HOBt
(2.3 g, 17.2 mmol) and DIEA (3.7 mL, 20.7 mmol). The resulting
solution was stirred at RT overnight. The residue was treated with
water and extracted with DCM. The organic extracts were washed with
brine, dried over anhydrous Na.sub.2SO.sub.4, filtered and
concentrated to give a crude oil. The crude product was purified by
silica gel chromatography to afford Compound 2 (2.3 g, 61.5%).
[0185] 2. To a solution of Compound 2 (1 g, 4.6 mmol) in dry THF
(10 mL) at 0.degree. C. under N.sub.2 was added MeMgBr (2 mL, 3.0
mol/L, 6 mmol) dropwise. The resulting solution was slowly warmed
to RT over 2 hours. The reaction was diluted with NH.sub.4Cl
solution and extracted with EA. The organic extracts were
concentrated to give a crude oil. The crude product was purified by
silica gel chromatography to afford Compound 3 (600 mg, 75.7%).
[0186] 3. To a solution of 2-chlorothiazole (1 g, 8.4 mmol) in dry
THF (10 mL) at -78.degree. C. under N.sub.2 was added n-BuLi (3.5
mL, 9.2 mmol) dropwise. After 1 hour a solution of Compound 3 (1.3
g, 7.6 mmol) in dry THF (5 mL) was added dropwise at -78.degree. C.
The resulting solution was slowly warmed to RT. The reaction was
diluted with NH.sub.4Cl solution and extracted with EA. The organic
extracts were concentrated to give a crude oil. The crude product
was purified by silica gel chromatography to afford Compound 4 (1.6
g, 72.6%).
[0187] .sup.1H NMR (CDCl.sub.3, 300 MHz) .delta.: 2.0-2.1 (s, 3H),
4.1-4.2 (s, 1H), 7.3-7.4 (s, 1H), 7.8-7.9 (d, 1H), 8.0-8.1 (d, 1H),
8.3 (s, 1H), 8.8 (s, 2H). [0188] 4. To a solution of Compound 4
(1.2 g, 4.1 mmol) in DCE (30 mL) was added TES-H (1.4 mg, 12.3
mmol). Then TFA (4.7 mg, 41 mmol) was added dropwise at 0.degree.
C. The resulting solution was stirred at 60.degree. C. for 4 hours.
The residue was concentrated and purified by silica gel
chromatography to afford Compound 5 (0.6 g, 52.8%). [0189] 5. To a
solution of Compound 5 (600 mg, 2.2 mmol) in DMF (5 mL) were added
4-benzylpiperidine (570 mg, 3.3 mmol)) and K.sub.2CO.sub.3 (600 mg,
4.4 mmol). The reaction mixture was stirred at 80.degree. C.
overnight. After cooling to RT, the residue was treated with water
and extracted with EA. The organic extracts were washed with water,
brine, dried over anhydrous Na.sub.2SO.sub.4, filtered and
concentrated to give a crude oil. The crude product was purified by
silica gel chromatography to afford Example 11 (50 mg, 5.5%).
[0190] .sup.1H NMR (CDCl.sub.3, 300 MHz) .delta.: 1.4-1.5 (m, 2H),
1.6-1.7 (s, 5H), 1.8-2.0 (m, 2H), 2.6-2.7 (d, 2H), 3.1-3.2 (t, 2H),
4.2-4.3 (t, 2H), 7.2-7.4 (m, 5H), 7.8-7.9 (s, 1H), 8.2-8.3 (m, 2H),
8.5-8.6 (s, 1H), 9.0 (s, 2H).
[0191] LC-MS: m/z=415 (M+1).sup.+.
Synthesis of Example 12:
##STR00030##
[0193] Procedure: [0194] 1. To a solution of Compound 1 (3 g, 17.2
mmol) in DCM (80 mL) were added N,O-dimethylhydroxylamine
hydrochloride (2.0 g, 20.7 mmol), EDCI (4.0 g, 20.7 mmol), HOBt
(2.3 g, 17.2 mmol) and DIEA (3.7 mL, 20.7 mmol). The resulting
solution was stirred at RT overnight. The residue was treated with
water and extracted with DCM. The organic extracts were washed with
brine, dried over anhydrous Na.sub.2SO.sub.4, filtered and
concentrated to give a crude oil. The crude product was purified by
silica gel chromatography to afford Compound 2 (2.3 g, 61.5%).
[0195] 2. To a solution of Compound 2 (1 g, 4.6 mmol) in dry THF
(10 mL) at 0.degree. C. under N.sub.2 was added MeMgBr (2 mL, 3.0
mol/L, 6 mmol) dropwise. The resulting solution was slowly warmed
to RT over 2 hours. The reaction was diluted with NH.sub.4Cl
solution and extracted with EA. The organic extracts were
concentrated to give a crude oil. The crude product was purified by
silica gel chromatography to afford Compound 3 (600 mg, 75.7%).
[0196] 3. To a solution of 2-chlorothiazole (1 g, 8.4 mmol) in dry
THF (10 mL) at -78.degree. C. under N.sub.2 was added n-BuLi (3.5
mL, 9.2 mmol) dropwise. After 1 hour stirring at this tempa
solution of Compound 3 (1.3 g, 7.6 mmol) in dry THF (5 mL) was
added dropwise at -78.degree. C. The resulting solution was slowly
warmed to RT. The reaction was diluted with NH.sub.4Cl solution and
extracted with EA. The organic extracts were concentrated to give a
crude oil. The crude product was purified by silica gel
chromatography to afford Compound 4 (1.6 g, 72.6%).
[0197] .sup.1H NMR (CDCl.sub.3, 300 MHz) .delta.: 2.0-2.1 (s, 3H),
4.1-4.2 (s, 1H), 7.3-7.4 (s, 1H), 7.8-7.9 (d, 1H), 8.0-8.1 (d, 1H),
8.3 (s, 1H), 8.8 (s, 2H). [0198] 4. To a solution of Compound 4
(1.2 g, 4.1 mmol) in DCE (30 mL) was added TES-H (1.4 mg, 12.3
mmol), the mixture cooled to 0.degree. C. and TFA (4.7 mg, 41 mmol)
was added dropwise. The resulting solution was stirred at
60.degree. C. for 4 hours. The residue was concentrated and
purified by silica gel chromatography to afford Compound 5 (0.6 g,
52.8%). [0199] 5. To a solution of Compound 5 (300 mg, 1.1 mmol) in
DMF (5 mL) were added benzylamine (188 mg, 2.2 mmol)) and
K.sub.2CO.sub.3 (300 mg, 2.2 mmol). The reaction mixture was
stirred at 80.degree. C. overnight. After cooling to RT, the
residue was treated with water and extracted with EA. The organic
extracts were washed with water, brine, dried over anhydrous
Na.sub.2SO.sub.4, filtered and concentrated to give a crude oil.
The crude product was purified by silica gel chromatography to
afford Example 12 (20 mg, 5.3%).
[0200] .sup.1H NMR (CDCl.sub.3, 300 MHz) .delta.: 4.4-4.5 (t, 2H),
5.5-5.2 (t, 1H), 6.9 (s, 1H), 7.5-7.2 (m, 5H), 7.8-7.9 (d, 1H),
8.2-8.1 (d, 1H), 8.3-8.2 (s, 1H), 9.0-8.9 (m, 1H).
[0201] LC-MS: m/z=345.2 (M+1).sup.+.
Synthesis of Examples 13 and 14:
##STR00031##
[0203] Procedure: [0204] 1. To a solution of Compound 1 (10 g, 72.5
mmol) in dry DMF (100 mL) were added pyrazole (10 g, 145 mmol),
K.sub.2CO.sub.3 (20 g, 145 mmol) and 18-crown-6 (2 g). The
resulting solution was stirred at 130.degree. C. for 4 hours. After
cooling to RT, the residue was treated with water and extracted
with EA. The organic extracts were washed with water, brine, dried
over anhydrous Na.sub.2SO.sub.4, filtered and concentrated to give
a crude oil. The crude product was purified by recrystallization to
afford Compound 2 (3.5 g, 26%).
[0205] .sup.1HNMR (CDCl.sub.3, 300 MHz) .delta.: 2.6-2.7 (s, 3H),
6.4-6.5 (s, 1H), 7.7-7.9 (m, 3H), 8.0-8.2 (m, 3H). [0206] 2. To a
solution of 2-chlorothiazole (850 mg, 7 mmol) in dry THF (10 mL) at
-78.degree. C. under N.sub.2 was added n-BuLi (2.8 mL, 7 mmol)
dropwise. After 1 hour a solution of Compound 2 (1 g, 5.3 mmol) was
added dropwise at -78.degree. C. The resulting solution was slowly
warmed to RT. The reaction was diluted with NH.sub.4Cl solution and
extracted with EA. The organic extracts were concentrated to give a
crude oil. The crude product was purified by silica gel
chromatography to afford Compound 3 (600 mg, 37%).
[0207] .sup.1H NMR (CDCl.sub.3, 300 MHz) .delta.: 2.0-2.1 (s, 3H),
6.4-6.5 (s, 1H), 7.2-7.3 (s, 1H), 7.5-7.6 (d, 2H), 7.6-7.7 (d, 2H),
7.7-7.8 (s, 1H), 7.9-8.0 (s, 1H). [0208] 3. To a solution of
Compound 3 (1 g, 3.28 mmol) in DCE (20 mL) was added TES-H (1.1 g,
9.8 mmol), the mixture cooled to 0.degree. C. and TFA (3.7 g, 32.8
mmol) was added dropwise. The resulting solution was stirred at
60.degree. C. for 4 hours. The residue was concentrated and
purified by silica gel chromatography to afford Compound 4 (800 mg,
85%).
[0209] .sup.1H NMR (CDCl.sub.3, 300 MHz) .delta.: 5.4-5.6 (ss, 2H),
6.4-6.5 (s, 1H), 7.2-7.4 (m, 2H), 7.4-7.5 (d, 2H), 7.6-7.8 (m, 3H),
7.9-8.0 (s, 1H). [0210] 4. To a solution of Compound 4 (400 mg, 1.4
mmol) in DMF (10 mL) were added 1,2,3,4-tetrahydroisoquinoline (280
mg, 2.1 mmol)) and K.sub.2CO.sub.3 (390 mg, 2.8 mmol). The reaction
mixture was stirred at 80.degree. C. overnight. After cooling to
RT, the residue was treated with water and extracted with EA. The
organic extracts were washed with water, brine, dried over
anhydrous Na.sub.2SO.sub.4, filtered and concentrated to give a
crude oil. The crude product was purified by silica gel
chromatography to afford Example 14 (150 mg, 22.3%).
[0211] .sup.1H NMR (CDCl.sub.3, 300 MHz) .delta.: 3.0-3.1 (t, 2H),
3.7-3.8 (t, 2H), 4.6-4.7 (s, 2H), 5.1-5.3 (ss, 2H), 6.4-6.5 (s,
1H), 7.0-7.1 (s, 1H), 7.2-7.4 (m, 4H), 7.5-7.6 (d, 2H), 7.6-7.8 (m,
3H), 7.9-8.0 (s, 1H).
[0212] LC-MS: m/z=385.2 (M+1)+. [0213] 5. To a solution of Example
14 (150 mg, 0.4 mmol) in MeOH (10 mL) was added Pd/C (20 mg). The
reaction mixture was stirred at RT under a H.sub.2 balloon
overnight. The residue was filtered, the filter cake washed with
MeOH, the filtrate was concentrated and purified by silica gel
chromatography to afford Example 13 (40 mg, 27%).
[0214] .sup.1H NMR (CDCl.sub.3, 300 MHz) .delta.: 1.6-1.7 (d, 2H),
3.0-3.1 (t, 2H), 3.7-3.8 (t, 2H), 4.2-4.3 (m, 1H), 4.6-4.7 (s, 2H),
6.4-6.5 (s, 1H), 7.0-7.1 (s, 1H), 7.2-7.4 (m, 4H), 7.4-7.5 (d, 2H),
7.6-7.8 (m, 3H), 7.9-8.0 (s, 1H).
[0215] LC-MS: m/z=387.2 (M+1)+.
Synthesis of Example 15:
##STR00032##
[0217] Procedure: [0218] 1. To a solution of Compound 1 (10 g, 72.5
mmol) in dry DMF (100 mL) were added piperidine (12.6 g, 145 mmol),
K.sub.2CO.sub.3 (20 g, 145 mmol) and 18-crown-6 (2 g). The
resulting solution was stirred at 130.degree. C. for 4 hours. After
cooling to RT, the residue was treated with water and extracted
with EA. The organic extracts were washed with water, brine, dried
over anhydrous Na.sub.2SO.sub.4, filtered and concentrated to give
a crude oil. The crude product was purified by recrystallization to
afford Compound 2 (5 g, 34%). [0219] 2. To a solution of
2-chlorothiazole (3.5 g, 29.5 mmol) in dry THF (10 mL) at
-78.degree. C. under N.sub.2 was added n-BuLi (12 mL, 29.5 mmol)
dropwise. After 1 hour a solution of Compound 2 (5 g, 24.6 mmol)
was added dropwise. The resulting solution was slowly warmed to RT.
The reaction was diluted with NH.sub.4Cl solution and extracted
with EA. The organic extracts were concentrated to give a crude
oil. The crude product was purified by silica gel chromatography to
afford Compound 3 (2.9 g, 36.5%). [0220] 3. To a solution of
Compound 3 (1 g, 3.1 mmol) in DCE (20 mL) was added TES-H (1.1 g,
9.3 mmol), the mixture cooled to 0.degree. C. and TFA (3.5 g, 31
mmol) was added dropwise. The resulting solution was stirred at
60.degree. C. for 4 hours. The residue was concentrated and
purified by silica gel chromatography to afford Compound 4 (600 mg,
63.6%). [0221] 4. To a solution of Compound 4 (500 mg, 1.6 mmol) in
DMF (10 mL) were added 1,2,3,4-tetrahydroisoquinoline (330 mg, 2.5
mmol)) and K.sub.2CO.sub.3 (500 mg, 3.2 mmol). The reaction mixture
was stirred at 80.degree. C. overnight. After cooling to RT, the
residue was treated with water and extracted with EA. The organic
extracts were washed with water, brine, dried over anhydrous
Na.sub.2SO.sub.4, filtered and concentrated to give a crude oil.
The crude product was purified by silica gel chromatography to
afford Compound 5 (150 mg, 22.8%). [0222] 5. To a solution of
Compound 5 (150 mg, 0.37 mmol) in MeOH (10 mL) was added Pd/C (20
mg). The reaction mixture was stirred at RT under a H.sub.2 balloon
overnight. The residue was filtered, the filter cake washed with
MeOH, the filtrate was concentrated and purified by silica gel
chromatography to afford Example 15 (62 mg, 41%).
[0223] .sup.1H NMR (CDCl.sub.3, 300 MHz) .delta.: 1.6-1.7 (m, 7H),
2.9-3.0 (m, 2H), 3.0-3.1 (m, 4H), 3.6-3.7 (m, 2H), 4.0-4.1 (m, 1H),
4.6 (s, 1H), 6.9 (m, 3H), 7.1-7.2 (m, 6H).
[0224] LC-MS: m/z=404.2 (M+1)+.
Synthesis of Example 16:
##STR00033##
[0226] Procedure: [0227] 1. To a solution of Compound 1 (10 g, 80.6
mmol) in dry DMF (100 mL) were added pyrazole (5.5 g, 80.6 mmol)
and K.sub.2CO.sub.3 (12.2 g, 88.7 mmol). The resulting solution was
stirred at 100.degree. C. for overnight. After cooling to RT, the
residue was treated with water and extracted with EA. The organic
extracts were washed with water, brine, dried over anhydrous
Na.sub.2SO.sub.4, filtered and concentrated to give a crude oil.
The crude product was purified by recrystallization to afford
Compound 2 (4 g, 29%).
[0228] .sup.1H NMR (CDCl.sub.3, 300 MHz) .delta.: 6.5-6.6 (s, 1H),
7.7-7.8 (s, 1H), 7.9-8.0 (d, 2H), 8.0-8.1 (d, 2H), 8.1-8.2 (s, 1H),
10.0-10.1 (s, 1H). [0229] 2. To a solution of 2-chlorothiazole
(1.45 g, 12.1 mmol) in dry THF (10 mL) at -78.degree. C. under
N.sub.2 was added n-BuLi (5 mL, 12.1 mmol) dropwise. After 1 hour a
solution of Compound 2 (1.6 g, 9.3 mmol) was added dropwise at
-78.degree. C. The resulting solution was slowly warmed to RT. The
reaction was diluted with NH.sub.4Cl solution and extracted with
EA. The organic extracts were concentrated to give a crude oil. The
crude product was purified by silica gel chromatography to afford
Compound 3 (1.2 g, 50%).
[0230] .sup.1H NMR (CDCl.sub.3, 300 MHz) .delta.: 6.1-6.2 (s, 1H),
6.5-6.6 (s, 1H), 7.2-7.3 (s, 1H), 7.4-7.5 (d, 2H), 7.6-7.7 (d, 2H),
7.7-7.8 (s, 1H), 7.9-8.0 (s, 1H). [0231] 3. To a solution of
Compound 3 (1.2 g, 4.1 mmol) in DCE (20 mL) was added TES-H (1.4 g,
12.8 mmol), the mixture cooled to 0.degree. C. and TFA (4.7 g, 41
mmol) was added dropwise. The resulting solution was stirred at
60.degree. C. for 4 hours. The residue was concentrated and
purified by silica gel chromatography to afford Compound 4 (1 g,
91%).
[0232] .sup.1HNMR (CDCl.sub.3, 300 MHz) .delta.: 4.1-4.2 (s, 2H),
6.4-6.5 (s, 1H), 7.2-7.4 (m, 3H), 7.6-7.8 (m, 3H), 7.9-8.0 (s, 1H).
[0233] 4. To a solution of Compound 4 (500 mg, 1.8 mmol) in DMF (10
mL) were added 1,2,3,4-tetrahydroisoquinoline (362 mg, 2.7 mmol))
and K.sub.2CO.sub.3 (500 mg, 3.6 mmol). The reaction mixture was
stirred at 80.degree. C. overnight. After cooling to RT, the
residue was treated with water and extracted with EA. The organic
extracts were washed with water, brine, dried over anhydrous
Na.sub.2SO.sub.4, filtered and concentrated to give a crude oil.
The crude product was purified by silica gel chromatography to
afford Example 16 (50 mg, 7.4%).
[0234] .sup.1H NMR (CDCl.sub.3, 300 MHz) .delta.: 3.0-3.1 (t, 2H),
3.7-3.8 (t, 2H), 4.0-4.1 (s, 2H), 4.6-4.7 (s, 2H), 6.4-6.5 (s, 1H),
7.0-7.1 (s, 1H), 7.1-7.3 (m, 4H), 7.3-7.4 (d, 2H), 7.6-7.7 (d, 2H),
7.7-7.8 (s, 1H), 7.9-8.0 (s, 1H).
[0235] LC-MS: m/z=373.3 (M+1)+.
Synthesis of Example 17:
##STR00034## ##STR00035##
[0237] Procedure: [0238] 1. To a solution of compound 1 (2 g, 12.6
mmol) and compound 2 (2.2 g, 13.2 mmol) in CH.sub.3CN, was added
0.5M Na.sub.2CO.sub.3 (2.7 g, 25.2 mmol) and the mixture was purged
with N.sub.2 for 10 min. Pd(PPh.sub.3).sub.4 (800 mg) was then
added and the mixture heated at reflux overnight. The mixture was
filtered, diluted with water and extracted with EA. The resulting
aqueous mixture was acidified to pH=1 and a precipitate formed. The
precipitate was filtered and dried to give 2 g of compound 3.
[0239] 2. To a mixture of compound 3 (2 g, 10 mmol), EDCI (2.3 g,
12 mmol), HOBT (1.4 g, 10 mmol), DIEA (2.6 g, 20 mmol) and
N,O-dimethylhydroxylamine hydrochloride (1.2 g, 12 mmol) in DCM,
stirred at RT for 2 h. Water was added and extracted with DCM. The
extracts were concentrated to give 2.5 g of compound 4. [0240] 3.
To a solution of compound 4 (2.5 g, 10.3 mmol) in THF at
-78.degree. C. was added CH.sub.3MgBr (4.8 mL, 13.4 mmol) dropwise
The cooling bath was removed and the mixture stirred at RT for 1 h.
The mixture was diluted with water, extracted with EA, and the
extracts concentrated to give 1.7 g of compound 5. [0241] 4. To a
solution of 2-chlorothiazole (1.2 g, 9.4 mmol) in dry THF (10 mL)
at -78.degree. C. under N.sub.2 was added n-BuLi (4 mL, 9.4 mmol)
dropwise. After 1 hour a solution of Compound 5 (1.7 g, 8.6 mmol)
was added dropwise. The resulting solution was slowly warmed to RT.
The reaction was diluted with NH.sub.4Cl solution and extracted
with EA. The organic extracts were concentrated to give a crude
oil. The crude product was purified by silica gel chromatography to
afford 1.2 g of Compound 6. [0242] 5. To a solution of Compound 6
(400 mg, 1.4 mmol) in DMF (10 mL) were added
1,2,3,4-tetrahydroisoquinoline (280 mg, 2.1 mmol)) and
K.sub.2CO.sub.3 (390 mg, 2.8 mmol). The reaction mixture was
stirred at 80.degree. C. overnight. After cooling to RT, the
residue was treated with water and extracted with EA. The organic
extracts were washed with water, brine, dried over anhydrous
Na.sub.2SO.sub.4, filtered and concentrated to give a crude oil.
The crude product was purified by silica gel chromatography to
afford 34 mg of Compound 7 [0243] 6. To a solution of Compound 7 (1
g, 3.28 mmol) in DCE (20 mL) was added TES-H (1.1 g, 9.8 mmol), the
mixture cooled to 0.degree. C. and TFA (3.7 g, 32.8 mmol) was added
dropwise. The resulting solution was stirred at 60.degree. C. for 4
hours. The residue was concentrated and purified by silica gel
chromatography to afford 800 mg Compound 8 [0244] 7. To a solution
of Compound 8 (150 mg, 0.4 mmol) in MeOH (10 mL) was added Pd/C (20
mg). The reaction mixture was stirred at RT under a H.sub.2 balloon
overnight. The residue was filtered, the filter cake washed with
MeOH the filtrate was concentrated and purified by silica gel
chromatography to afford 34 mg of Example 17
[0245] .sup.1HNMR (CDCl.sub.3, 300 MHz) .delta.: 1.6-1.7 (d, 2H),
3.0-3.1 (t, 2H), 3.7-3.8 (t, 2H), 4.2-4.3 (m, 1H), 4.6-4.7 (s, 2H),
6.4-6.5 (s, 1H), 7.0-7.1 (s, 1H), 7.2-7.4 (m, 4H), 7.4-7.5 (d, 2H),
7.6-7.8 (m, 3H), 7.9-8.0 (s, 1H).
[0246] LC-MS: m/z=399 (M+1)+.
Synthesis of Examples 18 and 19:
##STR00036## ##STR00037##
[0248] Procedure: [0249] 1. To a solution of 3-hydrazinylbenzoic
acid (10 g, 65.7 mmol) in EtOH/H.sub.2O (200 mL, 1:1) was added
1,1,3,3-tetramethoxypropane (16 mL, 65.7 mmol). The resulting
solution was stirred at reflux for 2 hours. The solvent was removed
in vacuo, the residue was purified by recrystallization to afford
Compound 1 (9 g, 73%).
[0250] .sup.1HNMR (CDCl.sub.3, 300 MHz) .delta.: 6.5-6.6 (s, 1H),
7.5-7.7 (t, 1H), 7.7-7.8 (s, 1H), 8.0-8.2 (m, 3H), 8.4-8.5 (s, 1H).
[0251] 2. To a solution of Compound 1 (5 g, 26.6 mmol) in DCM (100
mL) were added N,O-dimethylhydroxylamine hydrochloride (3.1 g, 32
mmol), EDCI (6.1 g, 32 mmol), HOBt (3.6, 26.6 mmol) and DIEA (8.8
mL, 53.2 mmol). The resulting solution was stirred at RT overnight.
The residue was treated with water and extracted with DCM. The
organic extracts were washed with brine, dried over anhydrous
Na.sub.2SO.sub.4, filtered and concentrated to give a crude oil.
The crude product was purified by silica gel chromatography to
afford Compound 2 (3.2 g, 57%).
[0252] .sup.1H NMR (CDCl.sub.3, 300 MHz) .delta.: 3.3-3.4 (s, 3H),
3.5-3.6 (s, 3H), 6.4-6.5 (s, 1H), 7.4-7.5 (t, 1H), 7.5-7.6 (d, 1H),
7.7-7.8 (s, 1H), 7.8-7.9 (d, 1H), 7.9-8.0 (d, 2H). [0253] 3. To a
solution of Compound 2 (3 g, 13 mmol) in ether (30 mL) at 0.degree.
C. was added a solution of MeMgI in ether (20 mL, 19 mmol)
dropwise. The mixture was stirred at room-temp for 2 hours. The
mixture was diluted with saturated ammonium chloride at 0.degree.
C. The residue was treated with water and extracted with EA. The
organic extracts were washed with brine, dried over anhydrous
Na.sub.2SO.sub.4, filtered and concentrated to give a crude oil.
The crude product was purified by silica gel chromatography to
afford Compound 3 (2 g, 83.3%).
[0254] .sup.1H NMR (CDCl.sub.3, 300 MHz) .delta.: 2.6-2.7 (s, 3H),
6.4-6.5 (s, 1H), 7.5-7.6 (t, 1H), 7.7-7.8 (s, 1H), 7.8-8.1 (m, 3H),
8.2-8.3 (s, 1H). [0255] 4. To a solution of 2-chlorothiazole (1.7
g, 14 mmol) in dry THF (30 mL) at -78.degree. C. under
[0256] N.sub.2 was added n-BuLi (5.6 mL, 14 mmol) dropwise. After 1
hour a solution of Compound 3 (2 g, 10.6 mmol) was added dropwise.
The resulting solution was slowly warmed to RT. The reaction was
diluted with NH.sub.4Cl solution and extracted with EA. The organic
extracts were concentrated to give a crude oil. The crude product
was purified by silica gel chromatography to afford Compound 4 (1
g, 31%). [0257] 5. To a solution of Compound 4 (1.5 g, 4.29 mmol)
in DCE (30 mL) was added TES-H (1.65 g, 14.7 mmol), the mixture
cooled to 0.degree. C. and TFA (5.6 g, 49.2 mmol) was added
dropwise at 0.degree. C. The resulting solution was stirred at
60.degree. C. for 4 hours. The residue was concentrated and
purified by silica gel chromatography to afford Compound 5 (800 mg,
57%). [0258] 6. To a solution of Compound 5 (400 mg, 1.4 mmol) in
DMF (10 mL) were added 1,2,3,4-tetrahydroisoquinoline (280 mg, 2.1
mmol)) and K.sub.2CO.sub.3 (390 mg, 2.8 mmol). The reaction mixture
was stirred at 80.degree. C. overnight. After cooling to RT, the
residue was treated with water and extracted with EA. The organic
extracts were washed with water, brine, dried over anhydrous
Na.sub.2SO.sub.4, filtered and concentrated to give a crude oil.
The crude product was purified by silica gel chromatography to
afford Example 19 (120 mg, 18%).
[0259] .sup.1H NMR (CDCl.sub.3, 300 MHz) .delta.: 3.0-3.1 (t, 2H),
3.7-3.8 (t, 2H), 4.6-4.7 (s, 2H), 5.1-5.3 (ss, 2H), 6.4-6.5 (s,
1H), 7.0-7.1 (s, 1H), 7.1-7.3 (m, 4H), 7.3-7.5 (m, 2H), 7.6-7.8 (m,
3H), 7.9-8.0 (s, 1H).
[0260] LC-MS: m/z=385.2 (M+1)+. [0261] 7. To a solution of Example
19 (100 mg, 0.27 mmol) in MeOH (10 mL) was added Pd/C (10 mg). The
reaction mixture was stirred at RT under a H.sub.2 balloon
overnight. The residue was filtered, the filter cake washed with
MeOH, the filtrate was concentrated and purified by silica gel
chromatography to afford Example 18 (35 mg, 35%).
[0262] .sup.1H NMR (CDCl.sub.3, 300 MHz) .delta.: 1.6-1.7 (d, 2H),
3.0-3.1 (t, 2H), 3.7-3.8 (t, 2H), 4.2-4.3 (m, 1H), 4.6-4.7 (s, 2H),
6.4-6.5 (s, 1H), 7.0-7.1 (s, 1H), 7.2-7.4 (m, 4H), 7.4-7.5 (d, 2H),
7.6-7.8 (m, 3H), 7.9-8.0 (s, 1H).
[0263] LC-MS: m/z=387.2 (M+1)+.
Synthesis of Example 20:
##STR00038##
[0265] Procedure: [0266] 1. To a solution of Compound 1 (10 g, 54
mmol) in dry DMF (100 mL) were added pyrazole (3.7 g, 54 mmol),
Cs.sub.2CO.sub.3 (26.4 g, 81 mmol) and CuI (1 g, 5.4 mmol). The
resulting solution was stirred at 120.degree. C. for overnight.
After cooling to RT, the residue was treated with water and
extracted with EA. The organic extracts were washed with water,
brine, dried over anhydrous Na.sub.2SO.sub.4, filtered and
concentrated to give a crude oil. The crude product was purified by
silica gel chromatography to afford Compound 2 (4 g, 43%).
[0267] .sup.1HNMR (CDCl.sub.3, 300 MHz) .delta.: 6.5-6.6 (s, 1H),
7.6-7.7 (m, 1H), 7.7-7.9 (m, 2H), 8.0-8.1 (m, 2H), 8.2-8.3 (s, 1H),
10.0-10.1 (s, 1H). [0268] 2. To a solution of 2-chlorothiazole
(1.45 g, 12.1 mmol) in dry THF (10 mL) at -78.degree. C. under
N.sub.2 was added n-BuLi (5 mL, 12.1 mmol) dropwise. After 1 hour
solution of Compound 2 (1.6 g, 9.3 mmol) was added dropwise. The
resulting solution was slowly warmed to RT. The reaction was
diluted with NH.sub.4Cl solution and extracted with EA. The organic
extracts were concentrated to give a crude oil. The crude product
was purified by silica gel chromatography to afford Compound 3 (1.2
g, 50%).
[0269] .sup.1H NMR (CDCl.sub.3, 300 MHz) .delta.: 6.1-6.2 (s, 1H),
6.5-6.6 (s, 1H), 7.2-7.4 (t, 2H), 7.4-7.5 (t, 1H), 7.6-7.7 (d, 1H),
7.7-7.9 (ss, 2H), 7.9-8.0 (s, 1H). [0270] 3. To a solution of
Compound 3 (1.2 g, 4.1 mmol) in DCE (20 mL) was added TES-H (1.4 g,
12.8 mmol), the mixture cooled to 0.degree. C. and TFA (4.7 g, 41
mmol) was added dropwise. The resulting solution was stirred at
60.degree. C. for 4 hours. The residue was concentrated and
purified by silica gel chromatography to afford Compound 4 (1 g,
91%).
[0271] .sup.1H NMR (CDCl.sub.3, 300 MHz) .delta.: 4.2-4.3 (s, 2H),
6.4-6.5 (s, 1H), 7.1-7.2 (s, 1H), 7.3-7.4 (s, 1H), 7.4-7.5 (t, 1H),
7.5-7.6 (d, 1H), 7.6-7.7 (s, 1H), 7.7-7.8 (s, 1H), 7.9-8.0 (s, 1H).
[0272] 4. To a solution of Compound 4 (500 mg, 1.8 mmol) in DMF (10
mL) were added 1,2,3,4-tetrahydroisoquinoline (362 mg, 2.7 mmol))
and K.sub.2CO.sub.3 (500 mg, 3.6 mmol). The reaction mixture was
stirred at 80.degree. C. overnight. After cooling to RT, the
residue was treated with water and extracted with EA. The organic
extracts were washed with water, brine, dried over anhydrous
Na.sub.2SO.sub.4, filtered and concentrated to give a crude oil.
The crude product was purified by silica gel chromatography to
afford Example 20 (30 mg, 4.4%).
[0273] .sup.1H NMR (CDCl.sub.3, 300 MHz) .delta.: 2.9-3.0 (t, 2H),
3.6-3.7 (t, 2H), 4.0-4.1 (s, 2H), 4.6-4.7 (s, 2H), 6.4-6.5 (s, 1H),
7.0-7.1 (s, 1H), 7.1-7.3 (m, 4H), 7.3-7.4 (d, 2H), 7.5-7.6 (d, 2H),
7.7-7.8 (s, 1H), 7.9-8.0 (s, 1H).
[0274] LC-MS: m/z=373.2 (M+1)+.
Synthesis of Examples 21:
##STR00039##
[0276] Procedure: [0277] 1. To a solution of Compound 1 (30 g,
162.1 mmol) in dry DMF (200 mL) were added 1H-pyrazole (11 g, 162.1
mmol) and K.sub.2CO.sub.3 (24.8 g, 178.3 mmol). The resulting
solution was stirred at 80.degree. C. for 12 hours. After cooling
to RT, the residue was treated with water and extracted with EA.
The organic extracts were washed with water, brine, dried over
anhydrous Na.sub.2SO.sub.4, filtered and concentrated to give a
crude oil. The crude product was purified by recrystallization to
afford Compound 2 (25 g, 89%). [0278] 2. To a solution of
2-chlorothiazole (16.7 g, 139.5 mmol) in dry THF (200 mL) was added
n-BuLi (55.8 mL, 139.5 mmol) dropwise at -78.degree. C. under
N.sub.2. After 1 hour stirring at this temp. a solution of Compound
2 (20 g, 116 mmol) was added dropwise at -78.degree. C. The
resulting solution was allowed to slowly warmed to RT. The reaction
was diluted with NH.sub.4Cl solution and extracted with EA. The
organic extracts were concentrated to give a crude oil. The crude
product was purified by silica gel chromatography to afford
Compound 3 (15 g, 44.4%).
[0279] .sup.1H NMR (CDCl.sub.3, 300 MHz) .delta.: 4.0-4.1 (m, 1H),
5.9-6.0 (s, 1H), 6.5 (s, 1H), 7.2-7.3 (s, 1H), 7.4-7.5 (d, 2H),
7.6-7.7 (d, 2H), 7.7-7.8 (s, 1H), 7.9-8.0 (s, 1H). [0280] 3. To a
solution of Compound 3 (15 g, 51.5 mmol) in DCE (100 mL) was added
TES-H (17 g, 155 mmol) and TFA (58.7 g, 515 mmol) was added
dropwise at 0.degree. C. The resulting solution was stirred at
60.degree. C. over night. The residue was concentrated and purified
by silica gel chromatography to afford Compound 4 (8 g, 56.4%).
[0281] .sup.1H NMR (CDCl.sub.3, 300 MHz) .delta.: 4.1-4.2 (s, 1H),
5.5-5.6 (m, 1H), 6.5-6.6 (s, 1H), 7.2-7.4 (m, 3H), 7.6-7.7 (d, 2H),
7.7-7.8 (s, 1H), 7.9-8.0 (s, 1H). [0282] 4. To a solution of
Compound 4 (500 mg, 1.8 mmol) in DMSO (10 mL) were added benzyl
amine (600 mg, 5.4 mmol)) and K.sub.2CO.sub.3 (500 mg, 3.6 mmol).
The reaction mixture was stirred at 80.degree. C. overnight. After
cooling to RT, the residue was treated with water and extracted
with EA. The organic extracts were washed with water, brine, dried
over anhydrous Na.sub.2SO.sub.4, filtered and concentrated to give
a crude oil. The crude product was purified by silica gel
chromatography to afford Example 21 (45 mg, 7.2%).
[0283] .sup.1H NMR (CDCl.sub.3, 300 MHz) .delta.: 4.1-4.2 (s, 1H),
4.4-4.5 (m, 2H), 4.8-4.9 (m, 1H), 5.5-5.6 (m, 1H), 6.5 (s, 1H),
6.8-6.9 (s, 1H), 7.3-7.4 (m, 5H), 7.6-7.7 (d, 2H), 7.7-7.8 (s, 1H),
7.9 (s, 1H).
[0284] LC-MS: m/z=347.1 (M+1).sup.+.
[0285] The compounds listed in Table 1 below were prepared in a
similar manner to that described in Example 21, where the
conditions in step 4 are used substituting the appropriate amine as
indicated in Table 1.
TABLE-US-00001 TABLE 1 Example Amine Final Product Example 22
##STR00040## ##STR00041## Example 23 ##STR00042## ##STR00043##
Example 24 ##STR00044## ##STR00045## Example 25 ##STR00046##
##STR00047## Example 26 ##STR00048## ##STR00049## Example 27
##STR00050## ##STR00051## Example 28 ##STR00052## ##STR00053##
[0286] Spectral data for the examples listed in Table 1 are
presented below:
[0287] Example 22: (33 mg, 5.1%) .sup.1HNMR (CDCl.sub.3, 300 MHz)
.delta.: 1.1-1.2 (d, 6H), 3.6-3.7 (m, 2H), 3.9 (m, 2H), 4.0-4.1 (s,
2H), 4.2-4.3 (m, 2H), 4.5 (m, 1H), 6.4-6.5 (s, 1H), 6.9 (s, 1H),
7.3-7.4 (d, 2H), 7.6-7.7 (d, 2H), 7.7-7.8 (s, 1H), 7.9 (s, 1H).
[0288] LC-MS: m/z=355.2 (M+1).sup.+.
[0289] Example 23: (33 mg, 4.9%) .sup.1HNMR (CDCl.sub.3, 300 MHz)
.delta.: 2.0-2.1 (m, 2H), 2.7-2.8 (m, 2H), 3.8-3.9 (m, 2H), 4.0-4.1
(s, 2H), 6.4-6.5 (s, 1H), 6.9-7.0 (m, 1H), 7.1-7.2 (m, 3H), 7.3-7.4
(m, 3H), 7.6-7.7 (d, 2H), 7.7-7.8 (m, 2H), 7.9 (s, 1H).
[0290] LC-MS: m/z=373.1 (M+1).sup.+.
[0291] Example 24: (77 mg, 10.9%).sup.1HNMR (CDCl.sub.3, 300 MHz)
.delta.: 1.2-1.3 (d, 8H), 2.8-3.0 (s, 1H), 4.0-4.1 (s, 2H), 4.3-4.5
(s, 2H), 6.4-6.5 (s, 1H), 6.9 (s, 1H), 7.3-7.4 (d, 2H), 7.6-7.7 (d,
2H), 7.7-7.8 (s, 1H), 7.9 (s, 1H).
[0292] LC-MS: m/z=389.2 (M+1).sup.+.
[0293] Example 25: (33 mg, 4.8%) (CDCl.sub.3, 300 MHz) .delta.:
1.6-1.8 (m, 8H), 1.8-1.9 (m, 3H), 3.2-3.3 (m, 1H), 3.4-3.5 (m, 2H),
3.7-3.8 (m, 3H), 4.0 (s, 3H), 4.6-4.7 (s, 3H), 6.4-6.5 (s, 1H), 6.9
(s, 1H), 7.2-7.4 (m, 2H), 7.6-7.7 (d, 2H), 7.7-7.8 (s, 1H), 7.9 (s,
1H).
[0294] LC-MS: m/z=381.2 (M+1).sup.+.
[0295] Example 26: (150 mg, 22.8%) .sup.1HNMR (CDCl.sub.3, 300 MHz)
.delta.: 1.5 (m, 3H), 3.9-4.0 (d, 1H), 4.5-4.6 (m, 1H), 5.2-5.3 (m,
1H), 5.5-5.7 (m, 1H), 6.4-6.50 (s, 1H), 6.8-6.9 (s, 1H), 7.4-7.5
(s, 5H), 7.6-7.7 (d, 1H), 7.7-7.8 (s, 1H), 7.9 (s, 1H), 8.2-8.3 (s,
1H).
[0296] LC-MS: m/z=361.2 (M+1).sup.+.
[0297] Example 27: (44 mg, 6.7%) (CDCl.sub.3, 300 MHz) .delta.:
3.4-3.5 (m, 4H), 3.8-3.9 (m, 4H), 4.0-4.1 (s, 2H), 6.5 (s, 1H), 7.0
(s, 1H), 7.3-7.4 (m, 2H), 7.6-7.7 (d, 1H), 7.7-7.8 (s, 1H), 7.9-8.0
(s, 1H).
[0298] LC-MS: m/z=327.1 (M+1).sup.+.
[0299] Example 28: (32 mg, 4.4%) (CDCl.sub.3, 300 MHz) .delta.: 3.0
(m, 2H), 3.7-3.8 (m, 2H), 4.0-4.1 (s, 2H), 6.5 (s, 1H), 7.0 (s,
1H), 7.3-7.4 (m, 4H), 7.4-7.5 (s, 1H), 7.4-7.5 (s, 4H), 7.6-7.7 (s,
1H), 7.6-7.7 (d, 1H), 7.7-7.8 (s, 1H), 7.9-8.0 (s, 1H).
[0300] LC-MS: m/z=398.2 (M+1).sup.+.
Synthesis of Example 29:
##STR00054##
[0302] Procedure: [0303] 1. To a solution of Compound 1 (30 g,
162.1 mmol) in dry DMF (200 mL) were added 1H-pyrazole (11 g, 162.1
mmol), Cs.sub.2CO.sub.3 (58 g, 178.3 mmol), CuI (58 g), 18-Crown-6
(3 g). The resulting solution was stirred at 80.degree. C. for 24
hours. After cooling to RT, the residue was treated with water and
extracted with EA. The organic extracts were washed with water,
brine, dried over anhydrous Na.sub.2SO.sub.4, filtered and
concentrated to give a crude oil. The crude product was purified by
recrystallization to afford Compound 2 (20 g, 71.3%). [0304] 2. To
a solution of 2-chlorothiazole (10 g, 83.7 mmol) in dry THF (100
mL) was added n-BuLi (33.5 mL, 83.7 mmol) dropwise at -78.degree.
C. under N.sub.2. After 1 hour stirring at this temp. a solution of
Compound 2 (12 g, 69.7 mmol) was added dropwise at -78.degree. C.
The resulting solution was allowed to slowly warmed to RT. The
reaction was diluted with NH.sub.4Cl solution and extracted with
EA. The organic extracts were concentrated to give a crude oil. The
crude product was purified by silica gel chromatography to afford
Compound 3 (12 g, 59.2%).
[0305] .sup.1HNMR (CDCl.sub.3, 300 MHz) .delta.: 3.0-3.2 (m, 1H),
6.0-6.1 (s, 1H), 6.4-6.5 (s, 1H), 7.2-7.3 (d, 2H), 7.4-7.5 (d, 1H),
7.6-7.7 (d, 1H), 7.7-7.8 (s, 1H), 7.8-7.9 (s, 1H), 7.9-8.0 (s, 1H).
[0306] 3. To a solution of Compound 3 (10 g, 34.4 mmol) in DCE (60
mL) was added TES-H (11.3 g, 103.1 mmol). Then TFA (39.2 g, 344
mmol) was added dropwise at 0.degree. C. The resulting solution was
stirred at 60.degree. C. for over night. The residue was
concentrated and purified by silica gel chromatography to afford
Compound 4 (6 g, 79.4%).
[0307] .sup.1HNMR (CDCl.sub.3, 300 MHz) .delta.: 4.2-4.3 (s, 1H),
6.5-6.6 (m, 1H), 7.1-7.2 (d, 1H), 7.3-7.4 (s, 1H), 7.4-7.5 (t, 1H),
7.5-7.6 (d, 1H), 7.6-7.7 (s, 1H), 7.7-7.8 (s, 1H), 7.9-8.0 (s, 1H).
[0308] 4. To a solution of Compound 4 (500 mg, 1.8 mmol) in DMSO
(10 mL) were added benzylamine (600 mg, 5.4 mmol)) and
K.sub.2CO.sub.3 (500 mg, 3.6 mmol). The reaction mixture was
stirred at 80.degree. C. overnight. After cooling to RT, the
residue was treated with water and extracted with EA. The organic
extracts were washed with water, brine, dried over anhydrous
Na.sub.2SO.sub.4, filtered and concentrated to give a crude oil.
The crude product was purified by silica gel chromatography to
afford Example 29 (270 mg, 42.9%).
[0309] .sup.1HNMR (CDCl.sub.3, 300 MHz) .delta.: 4.0-4.1 (s, 1H),
4.4-4.5 (m, 2H), 5.2-5.3 (m, 1H), 6.4-6.5 (S, 1H), 6.9 (s, 1H),
7.1-7.2 (s, 1H), 7.3-7.4 (m, 5H), 7.5-7.6 (d, 2H), 7.7-7.8 (s, 1
H), 7.9-8.0 (s, 1H).
[0310] LC-MS: m/z=347.1 (M+1).sup.+.
The compounds listed in Table 2 below were prepared in a similar
manner to that described in Example 29, where the conditions in
step 4 are used substituting the appropriate amine as indicated in
Table 2.
TABLE-US-00002 TABLE 2 Example Amine Final Product Example 30
##STR00055## ##STR00056## Example 31 ##STR00057## ##STR00058##
Example 32 ##STR00059## ##STR00060## Example 33 ##STR00061##
##STR00062## Example 34 ##STR00063## ##STR00064## Example 35
##STR00065## ##STR00066## Example 36 ##STR00067## ##STR00068##
[0311] Spectral data for the examples listed in Table 2 are
presented below:
[0312] Example 30: (146.5 mg, 22.75%) .sup.1HNMR (CDCl.sub.3, 300
MHz) .delta.: 1.1-1.2 (d, 6H), 3.6-3.7 (m, 2H), 3.9 (m, 2H),
4.0-4.1 (s, 2H), 4.2-4.3 (m, 2H), 4.5 (m, 1H), 6.5 (s, 1H), 6.9-7.0
(s, 1H), 7.1-7.2 (d, 1H), 7.4 (d, 1H), 7.5-7.6 (d, 2H), 7.7-7.8 (s,
1H), 7.9-8.0 (s, 1H).
[0313] LC-MS: m/z=355.2 (M+1).sup.+.
[0314] Example 31: (55 mg, 8.1%) (CDCl.sub.3, 300 MHz) .delta.:
1.9-2.0 (m, 2H), 2.7-2.8 (m, 2H), 3.8-3.9 (m, 2H), 4.0-4.1 (s, 2H),
6.4-6.5 (s, 1H), 6.9-7.0 (m, 1H), 7.1-7.2 (m, 3H), 7.3-7.4 (m, 1H),
7.5-7.6 (d, 2H), 7.7-7.8 (m, 2H), 7.9 (s, 1H).
[0315] LC-MS: m/z=373.1 (M+1).sup.+.
[0316] Example 32: (68 mg, 9.6%) (CDCl.sub.3, 300 MHz) .delta.:
1.2-1.3 (d, 8H), 2.8-3.0 (s, 1H), 4.0-4.1 (s, 2H), 4.3-4.5 (s, 2H),
6.4-6.5 (s, 1H), 6.9 (s, 1H), 7.3-7.4 (m, 5H), 7.4-7.5 (m, 1H),
7.6-7.7 (d, 2H), 7.7-7.8 (s, 1H), 7.9 (s, 1H).
[0317] LC-MS: m/z=389.2 (M+1).sup.+.
[0318] Example 33: (171 mg, 24.7%) (CDCl.sub.3, 300 MHz) .delta.:
1.7-1.9 (m, 8H), 1.8-1.9 (m, 3H), 3.2-3.3 (m, 1H), 3.4-3.5 (m, 2H),
3.7-3.8 (m, 3H), 3.9-4.1 (s, 3H), 6.4-6.5 (s, 1H), 6.9 (s, 1H),
7.1-7.2 (m, 2H), 7.4 (d, 1H), 7.5-7.6 (m, 2H), 7.7-7.8 (s, 1H), 7.9
(s, 1H).
[0319] LC-MS: m/z=381.2 (M+1).sup.+.
[0320] Example 34: (43 mg, 6.6%) (CDCl.sub.3, 300 MHz) .delta.:
1.5-1.6 (s, 3H), 3.9-4.0 (m, 2H), 4.6-4.7 (m, 1H), 5.3-5.4 (m, 1H),
6.4-6.5 (s, 1H), 6.9 (s, 1H), 7.1-7.2 (d, 1H), 7.4-7.5 (s, 5H),
7.5-7.6 (s, 2H), 7.7-7.8 (s, 1H), 7.9 (s, 1H).
[0321] LC-MS: m/z=361.2 (M+1).sup.+.
[0322] Example 35: (37 mg, 6.2%) .sup.1HNMR (CDCl.sub.3, 300 MHz)
.delta.: 3.4-3.5 (m, 4H), 3.8 (m, 4H), 4.0-4.1 (s, 2H), 6.5 (s,
1H), 7.0 (s, 1H), 7.1-7.2 (d, 1H), 7.3-7.5 (m, 2H), 7.5-7.7 (m,
2H), 7.7-7.8 (s, 1H), 7.9-8.0 (s, 1H).
[0323] LC-MS: m/z=327.1 (M+1).sup.+.
[0324] Example 36: (32.5 mg, 4.5%) .sup.1HNMR (CDCl.sub.3, 300 MHz)
.delta.: 3.0 (m, 2H), 3.7-3.8 (m, 2H), 4.0-4.1 (s, 2H), 6.6-4.8 (m,
1H), 6.5 (s, 1H), 7.0 (s, 1H), 7.1-7.2 (s, 1H), 7.4-7.6 (s, 4H),
7.7-7.8 (s, 1H), 7.9-8.0 (s, 1H).
[0325] LC-MS: m/z=398.2 (M+1).sup.+.
Synthesis of Example SBX080:
##STR00069##
[0327] Procedure: [0328] 1. To a solution of Compound 1 (20 g, 99.5
mmol) in dry DCM (200 mL) were added N,O-dimethylhydroxylamine
hydrochloride (14.5 g, 149 mmol), EDCI (28.6 g, 149 mmol), HOBt
(14.8 g, 109 mmol), DIEA (38 g, 298 mmol) and the solution stirred
at RT for 24 hours. The mixture was diluted with water and
extracted with DCM. The combined extracts were washed with water,
brine, dried over anhydrous Na.sub.2SO.sub.4, filtered and
concentrated to give an oil. The crude product was purified to
afford Compound 2 (21.7 g, 89.3%). [0329] 2. A mixture of Compound
2 (20 g, 82 mmol), imidazole (6.2 g, 90 mmol), Cs.sub.2CO.sub.3 (29
g, 90 mmol), CuI (2 g), 18-Crown-6 (2 g) in dry DMF (200 mL) was
stirred at 80.degree. C. for 24 hours and cooled to RT. The mixture
was diluted with water and extracted with EA. The combined extracts
were washed with water, brine, dried over anhydrous
Na.sub.2SO.sub.4, filtered and concentrated to give an oil. The
crude product was purified by recrystallization to afford Compound
3 (14 g, 74.3%). [0330] 3. To a solution of Compound 3 (10 g, 43.2
mmol) in dry THF (80 mL) at 0.degree. C. under N.sub.2 was added
2.8 M MeMgBr (30.7 mL, 86 mmol) dropwise. The resulting solution
was warmed to RT and monitored by TLC. When TLC indicated the
reaction was complete, it was diluted with NH.sub.4Cl solution and
extracted with EA. The combined extracts were concentrated to give
an oil. The crude product was purified by silica gel chromatography
to afford Compound 4 (5.5 g, 68.3%).
[0331] .sup.1HNMR(CDCl.sub.3, 300 MHz) .delta.: 2.7-2.8 (s, 3H),
6.5 (s, 1H), 7.2-7.3 (s, 1H), 7.5-7.6 (m, 1H), 7.8-7.9 (d, 2H),
7.9-8.0 (d, 1H), 8.0-8.1 (s, 1H), 8.2-8.4 (s, 1H). [0332] 4. To a
solution of 2-chlorothiazole (5.5 g, 45.8 mmol) in dry THF (100 mL)
at -78.degree. C. was added n-BuLi (18.3 mL, 45.8 mmol) dropwise.
After 1 hour a solution of Compound 4 (7.1 g, 38.2 mmol) was added
dropwise. The resulting solution was warmed to RT. The reaction was
diluted with NH.sub.4Cl solution and extracted with EA. The
combined extracts were concentrated to give an oil which was
purified by silica gel chromatography to afford Compound 5 (9 g,
77%).
[0333] .sup.1HNMR(CDCl.sub.3, 300 MHz) .delta.: 2.0-2.1 (s, 3H),
2.9-3.1 (s, 1H), 6.4-6.5 (s, 1H), 7.3 (s, 1H), 7.4-7.5 (m, 3H),
7.6-7.7 (d, 1H), 7.7-7.8 (s, 1H), 7.9-8.0 (d, 2H). [0334] 5. To a
mixture of Compound 5 (9 g, 29.4 mmol) and TFA (21.9 mL, 294 mmol)
in DCE (60 mL) at 0.degree. C. was added triethylsilane (TES, 17.8
mL, 88.2 mmol) dropwise. The resulting solution was stirred at RT 3
h. The reaction was diluted with H.sub.2O and extracted with DCM.
The combined extracts were concentrated to give an oil and purified
by silica gel chromatography to afford Compound 6 (6.6 g,
78.5%).
[0335] .sup.1HNMR(CDCl.sub.3, 300 MHz) .delta.: 5.4-5.5 (s, 1H),
5.5-5.6 (s, 1H), 6.4-6.5 (s, 1H), 7.3 (s, 1H), 7.4-7.5 (m, 2H),
7.6-7.7 (d, 1H), 7.7-7.8 (s, 1H), 7.9-8.0 (d, 2H), 8.1-8.2 (s, 1H).
[0336] 6. To a solution of Compound 6 (6.6 g, 22.9 mmol) in EtOH
(60 mL) was added NaBH.sub.4 (25.8 g, 68 mmol) in three portions.
The resulting solution was stirred at RT for 6 h. The reaction was
concentrated, diluted with H.sub.2O and extracted with EA. The
combined extracts were concentrated to give a crude oil and
purified by silica gel chromatography to afford Compound 7 (4.8 g,
72.6%).
[0337] .sup.1HNMR (CDCl.sub.3, 300 MHz) .delta.: 1.7-1.8 (d, 3H),
3.4-3.5 (m, 1H), 5.5-5.7 (s, 1H), 7.1-7.2 (s, 1H), 7.2-7.3 (d, 2H),
7.4-7.5 (d, 1H), 7.6-7.7 (d, 1H), 7.7-7.8 (s, 1H), 7.8-7.9 (s, 1H),
7.9-8.0 (s, 1H). [0338] 7. To a solution of Compound 7 (300 mg, 1
mmol) in DMSO (3 mL) were added
1,2,3,4-tetrahydroisoquinoline-7-carbonitrile hydrochloride (290
mg, 1.5 mmol)) and K.sub.2CO.sub.3 (270 mg, 2 mmol). The reaction
mixture was stirred at 140.degree. C. overnight, cooled to RT and
the mixture was diluted with water and extracted with EA. The
combined organic extracts were washed with water, brine, dried over
anhydrous Na.sub.2SO.sub.4, filtered and concentrated to give an
SBX080 (56 mg, 13.2%).
[0339] .sup.1HNMR (CDCl.sub.3, 300 MHz) .delta.: 2.6-2.8 (m, 3H),
2.9-3.1 (m, 2H), 3.4-3.5 (s, 2H), 3.7-3.8 (m, 2H), 4.2-4.3 (s, 1H),
4.6-4.7 (s, 2H), 6.9-7.0 (s, 1H), 7.1-7.2 (s, 1H), 7.3 (s, 4H),
7.4-7.5 (m, 3H), 7.6-7.7 (m, 1H), 7.7-7.8 (d, 1H). LC-MS: m/z=412
(M+1)
Preparation of Intermediate 1
##STR00070##
[0341] Procedure: [0342] 1. A mixture of Compound 1 (30 g, 162.1
mmol), 1H-pyrazole (11 g, 162.1 mmol), Cs.sub.2CO.sub.3 (58 g,
178.3 mmol), CuI (3 g), 18-Crown-6 (3 g) in dry DMF (200 mL) was
stirred at 80.degree. C. for 24 hours and cooled to RT. The mixture
was diluted with water and extracted with EA. The combined extracts
were washed with water, brine, dried over anhydrous
Na.sub.2SO.sub.4, filtered and concentrated to give an oil. The
crude product was purified by recrystallization to afford Compound
2 (21 g, 75.3%). [0343] 2. To a solution of 2-chlorothiazole (10 g,
83.7 mmol) in dry THF (100 mL) at -78.degree. C. was added n-BuLi
(33.5 mL, 83.7 mmol) dropwise. After 1 hour a solution of Compound
2 (12 g, 69.7 mmol) was added dropwise. The resulting solution was
warmed to RT. The mixture was diluted with NH.sub.4Cl solution and
extracted with EA. The combined extracts were concentrated to give
an oil. The crude product was purified by silica gel chromatography
to afford Compound 3 (11.5 g, 68%).
[0344] .sup.1HNMR (CDCl.sub.3, 300 MHz) .delta.: 3.7-3.8 (s, 1H),
6.0-6.1 (s, 1H), 6.5-6.6 (s, 1H), 7.2-7.4 (d, 2H), 7.4-7.5 (d, 1H),
7.6-7.7 (d, 1H), 7.7-7.8 (s, 1H), 7.8-7.9 (s, 1H), 7.9-8.0 (s, 1H).
[0345] 3. To a solution of Compound 3 (5 g, 17 mmol) in THF (30 mL)
at 0.degree. C. was added NaH (1 g, 26 mmol) slowly and the mixture
stirred for 30 minutes. Mel (3.6 g, 26 mmol) was added dropwise at
0.degree. C., the cooling bath was removed and the mixture was
stirred at RT for 2 hours. The mixture was diluted with H.sub.2O
and extracted with EA. The combined extracts were concentrated to
give an oil which was purified by silica gel chromatography to
afford Intermediate 1 (3.6 g, 69.4%).
[0346] .sup.1HNMR(CDCl.sub.3, 300 MHz) .delta.: 3.4-3.5 (s, 3H),
5.7-5.8 (s, 1H), 6.4-6.5 (s, 1H), 7.2-7.3 (d, 2H), 7.4-7.5 (d, 1H),
7.6-7.7 (d, 1H), 7.7-7.8 (s, 1H), 7.8-7.9 (s, 1H), 7.9-8.0 (s,
1H).
Preparation of Intermediate 2
##STR00071##
[0348] Procedure: [0349] 1. To a solution of Compound 1 (20 g, 99.5
mmol) in dry DCM (200 mL) were added N,O-dimethylhydroxylamine
hydrochloride (14.5 g, 149 mmol), EDCI (28.6 g, 149 mmol), HOBt
(14.8 g, 109 mmol), DIEA (38 g, 298 mmol) and the solution stirred
at RT for 24 hours. The mixture was diluted with water and
extracted with DCM. The combined extracts were washed with water,
brine, dried over anhydrous Na.sub.2SO.sub.4, filtered and
concentrated to give an oil. The crude product was purified to
afford Compound 2 (20.7 g, 84.3%). [0350] 2. A mixture of Compound
2 (20 g, 82 mmol), 1H-pyrazole (6.2 g, 90 mmol), Cs.sub.2CO.sub.3
(29 g, 90 mmol), CuI (2 g), 18-Crown-6 (2 g) in dry DMF (200 mL)
was stirred at 80.degree. C. for 24 hours and cooled to RT. The
mixture was diluted with water and extracted with EA. The combined
extracts were washed with water, brine, dried over anhydrous
Na.sub.2SO.sub.4, filtered and concentrated to give an oil. The
crude product was purified by recrystallization to afford Compound
3 (14.9 g, 79.3%). [0351] 3. To a solution of Compound 3 (14 g,
60.5 mmol) in dry THF (100 mL) at 0.degree. C. under N.sub.2 was
added 2.8 M MeMgBr (43 mL, 121 mmol) dropwise. The mixture was
warmed to RT and monitored by TLC. When TLC indicated the reaction
was complete, it was diluted with NH.sub.4Cl solution and extracted
with EA. The combined extracts were concentrated to give an oil.
The crude product was purified by silica gel chromatography to
afford Compound 4 (7.1 g, 62.8%).
[0352] .sup.1HNMR (CDCl.sub.3, 300 MHz) .delta.: 2.7-2.8 (s, 3H),
6.5 (s, 1H), 7.2-7.3 (s, 1H), 7.5-7.6 (m, 1H), 7.7-7.8 (s, 1H),
7.8-7.9 (d, 1H), 7.9-8.0 (d, 1H), 8.0-8.1 (s, 1H), 8.2-8.4 (s, 1H).
[0353] 4. To a solution of 2-chlorothiazole (5.5 g, 45.8 mmol) in
dry THF (100 mL) at -78.degree. C. under N.sub.2 was added 2.5 M
n-BuLi (18.3 mL, 45.8 mmol) dropwise. After 1 hour at -78.degree.
C. a solution of Compound 4 (7.1 g, 38.2 mmol) in THF was added
dropwise. The resulting mixture was warmed to RT, diluted with
NH.sub.4Cl solution and extracted with EA. The combined extracts
were concentrated to give an oil. The crude product was purified by
silica gel chromatography to afford Compound 5 (7.9 g, 67%).
[0354] .sup.1HNMR (CDCl.sub.3, 300 MHz) .delta.: 2.0-2.2 (m, 3H),
3.0 (m, 1H), 6.4-6.5 (s, 1H), 7.3-7.5 (m, 3H), 7.7-7.9 (m, 3H),
8.1-8.2 (s, 1H). [0355] 5. To a mixture of Compound 5 (7.9 g, 25.8
mmol) and TFA (18.9 mL, 258 mmol) in DCE (60 mL) at 0.degree. C.
was added triethylsilane (TES, 15.8 mL, 77.4 mmol) dropwise. The
resulting solution was stirred at RT 3 h. The reaction was diluted
with H.sub.2O and extracted with DCM. The combined extracts were
concentrated to give an oil which was purified by silica gel
chromatography to afford Compound 6 (5.6 g, 75.7%).
[0356] .sup.1HNMR(CDCl.sub.3, 300 MHz) .delta.: 5.4-5.5 (s, 1H),
5.5-5.6 (s, 1H), 6.4-6.5 (s, 1H), 7.3 (s, 1H), 7.4-7.5 (m, 3H),
7.6-7.7 (d, 2H), 7.7-7.8 (s, 1H), 8.2-8.4 (s, 1H). [0357] 6. To a
solution of Compound 6 (5.6 g, 19.5 mmol) in EtOH (60 mL) was added
NaBH.sub.4 (21.9 g, 58.4 mmol) in three portions. The resulting
solution was stirred at RT for TLC. The reaction was concentrated,
diluted with H.sub.2O and extracted with EA. The combined extracts
were concentrated to give a crude oil and purified by silica gel
chromatography to afford Intermediate 2 (3.8 g, 66.6%).
[0358] .sup.1HNMR (CDCl.sub.3, 300 MHz) .delta.: 2.0-2.1 (d, 3H),
6.4-6.5 (s, 1H), 6.9-7.0 (s, 1H), 7.2 (d, 1H), 7.6-7.7 (m, 1H),
7.7-7.8 (d, 1H), 7.9-8.0 (d, 1H).
Example SBX082
##STR00072##
[0360] Procedure:
[0361] To a solution of Intermediate 2 (300 mg, 1 mmol) in DMSO (3
mL) were added 1,2,3,4-tetrahydroisoquinoline-7-carbonitrile
hydrochloride (290 mg, 1.5 mmol) and K.sub.2CO.sub.3 (270 mg, 2
mmol) and the resulting mixture was stirred at 140.degree. C.
overnight, cooled to RT, diluted with water and extracted with EA.
The combined extracts were washed with water, brine, dried over
anhydrous Na.sub.2SO.sub.4, filtered and concentrated to give an
oil. The crude product was purified by silica gel chromatography to
afford SBX082 (15 mg, 3.5%).
[0362] .sup.1HNMR (CDCl.sub.3, 300 MHz) .delta.: 1.6-1.8 (d, 3H),
3.0 (m, 2H), 3.6-3.8 (s, 2H), 4.2-4.3 (m, 1H), 4.6-4.7 (s, 2H),
6.4-6.5 (s, 1H), 6.9-7.0 (s, 1H), 7.2 (d, 1H), 7.4-7.6 (m, 4H),
7.6-7.7 (m, 1H), 7.7-7.8 (d, 1H), 7.9-8.0 (d, 1H). LC-MS: m/z=412
(M+1).sup.+.
Example SBX084
##STR00073##
[0364] Procedure:
[0365] Following the procedure described for Example SBX082,
Intermediate 2 (300 mg, 1 mmol) and
7-bromo-1,2,3,4-tetrahydroisoquinoline hydrochloride (290 mg, 1.5
mmol) were converted to SBX084 (98 mg, 20.4%).
[0366] .sup.1HNMR (CDCl.sub.3, 300 MHz) .delta.: 1.6-1.8 (d, 3H),
2.8-2.9 (m, 2H), 3.6-3.8 (s, 2H), 4.2-4.3 (m, 1H), 4.6-4.7 (s, 2H),
6.4-6.5 (s, 1H), 7.0-7.1 (s, 1H), 7.2 (d, 1H), 7.4-7.6 (m, 4H),
7.6-7.7 (m, 1H), 7.7-7.8 (d, 1H), 7.9-8.0 (d, 1H). LC-MS:
m/z=465/467 (M+1)
Example SBX087
##STR00074##
[0368] Procedure:
[0369] To a solution of Intermediate 1 (300 mg, 1 mmol) in DMSO (3
mL) were added 1,2,3,4-tetrahydroisoquinoline-7-carboxamide
hydrochloride (290 mg, 1.5 mmol)) and K.sub.2CO.sub.3 (270 mg, 2
mmol). The reaction mixture was stirred at 140.degree. C.
overnight. The mixture was cooled to RT, diluted with water and
extracted with EA. The combined extracts were washed with water,
brine, dried over anhydrous Na.sub.2SO.sub.4, filtered and
concentrated to give an oil which was purified by silica gel
chromatography to afford SBX087 (14 mg, 3.2%).
[0370] .sup.1HNMR (CDCl.sub.3, 300 MHz) .delta.: 2.9-3.0 (m, 2H),
3.3-3.4 (s, 3H), 3.7-3.8 (m, 2H), 4.6-4.7 (s, 2H), 5.4-5.5 (s, 1H),
6.4-6.5 (s, 1H), 7.0-7.1 (s, 1H), 7.3 (s, 1H), 7.4-7.5 (m, 2H),
7.6-7.7 (d, 1H), 7.7-7.8 (d, 2H), 7.9-8.0 (s, 1H). LC-MS: m/z=446
(M+1)
Example SBX088
##STR00075##
[0372] Procedure:
[0373] Following the procedure described for Example SBX082,
Intermediate 2 (300 mg, 1 mmol) and
1,2,3,4-tetrahydroisoquinoline-7-carboxamide hydrochloride (290 mg,
1.5 mmol) were converted to SBX088 (52 mg, 11.7%).
[0374] .sup.1HNMR (CDCl.sub.3, 300 MHz) .delta.: 1.6-1.8 (d, 3H),
2.8-2.9 (m, 2H), 3.6-3.8 (s, 2H), 4.2-4.3 (m, 1H), 4.6-4.7 (s, 2H),
6.4-6.5 (s, 1H), 7.0-7.1 (s, 1H), 7.2 (d, 1H), 7.4-7.6 (m, 4H),
7.6-7.7 (m, 1H), 7.7-7.8 (d, 1H), 7.9-8.0 (d, 1H). LC-MS: m/z=430.5
(M+1)
Assessing Antiviral Activity Against Human Cytomegalovirus
(HCMV)
[0375] To assess their antiviral activity, some compounds were
tested against human cytomegalovirus (HCMV) in vitro. Human MRCS
cells were grown in Dulbecco's Modified Eagle Medium (DMEM)
supplemented with 10% fetal bovine serum (FBS) and infected with an
HCMV variant expressing GFP tagged pUL99 (the product of late viral
UL99 gene) at a multiplicity of 1 infectious unit (IU) per cell.
One hour later, medium of the cells was replaced with fresh medium
containing the indicated compounds at 50, 25, 12.5, 6.25, 3.13,
1.56, 0.78, 0.39 .mu.M or the carrier in which the compounds are
dissolved (DMSO). Final concentration of DMSO was 0.5% in each
treatment. Virus yield in the culture supernatant was determined at
96 hours after infection by infecting fresh MRCS cells and assaying
viral IE1 protein expression. Results were plotted using either
Prism Software or CDD Vault (CDD Vault was developed by
Collaborative Drug Discovery, Inc., 1633 Bayshore Hwy, Suite 342,
Burlingame, Calif. 94010) in order to calculate IC50s.
[0376] Alternatively, antiviral efficacy of some compounds was
assessed by inhibition of HCMV replication during in vitro
replication assays. Briefly, confluent monolayers of MRCS
fibroblasts in a 96 well plate format
(.about.1.0.times.10{circumflex over ( )}4 cells/well) were
infected with an AD169 strain of HCMV for one hour. After the
initial incubation hour, virus containing media was removed and 100
ul of media with sequential dilutions of FORGE compounds added to
each well. The concentrations of the FORGE compounds were 50 .mu.M,
25 .mu.M, 12.5 .mu.M, 6.25 .mu.M, 3.125 .mu.M, 1.56 .mu.M, and
0.78125 .mu.M as well as a vehicle control (0.5% DMSO). The
concentration of DMSO was constant between all conditions. Assays
were performed in duplicate. Infected plates were returned to the
incubator and the viral infection was allowed to progress for four
days. On the fourth day, 50 .mu.L of cell free supernatant was
collected from each well and used to infect a new 96 well plate
seeded with a confluent monolayer of MRCS fibroblasts along with 50
.mu.L of media to bring the total volume to 100 .mu.L. The next day
the media was removed and the infected monolayer was fixed with
cold methanol, and Immediate Early proteins were detected by
immunofluorescence assays to quantify the number of cells that were
infected with HCMV. IE gene expression was quantified within five
random fields within each well and corresponding numbers were
utilized to determine viral replication. Results from each well
were normalized to the vehicle control well so as to allow a
percent reduction from no drug treatment to be calculated. Results
were plotted using either Prism Software or CDD Vault in order to
calculate IC50s.
[0377] As shown in Table 3, 28 of the tested compounds showed
antiviral activity against HCMV at IC.sub.50 values <50 .mu.M
without inducing cytotoxicity in the cells at antiviral
concentrations.
TABLE-US-00003 TABLE 3 Example Structure HCMV IC.sub.50 Example 1
##STR00076## 21.4 .mu.M Example 2 ##STR00077## 24.0 .mu.M Example 3
##STR00078## >50 .mu.M Example 4 ##STR00079## 5.6 .mu.M Example
5 ##STR00080## >50 .mu.M Example 6 ##STR00081## 5.1 .mu.M
Example 7 ##STR00082## >50 .mu.M Example 8 ##STR00083## 16.4
.mu.M Example 9 ##STR00084## 12.7 .mu.M Example 10 ##STR00085##
>25 .mu.M Example 11 ##STR00086## >25 .mu.M Example 12
##STR00087## >50 .mu.M Example 13 ##STR00088## 3.6 .mu.M Example
14 ##STR00089## 28.7 .mu.M Example 15 ##STR00090## >25 .mu.M
Example 16 ##STR00091## 12.5 .mu.M Example 17 ##STR00092## 4.2
.mu.M Example 18 ##STR00093## 1.6 .mu.M Example 19 ##STR00094## 7.0
.mu.M Example 20 ##STR00095## 8.9 .mu.M Example 21 ##STR00096##
>50 .mu.M Example 22 ##STR00097## >50 .mu.M Example 23
##STR00098## >50 .mu.M Example 24 ##STR00099## >50 .mu.M
Example 25 ##STR00100## 11 .mu.M Example 26 ##STR00101## >50
.mu.M Example 27 ##STR00102## 10.3 .mu.M Example 28 ##STR00103##
9.7 .mu.M Example 29 ##STR00104## >50 .mu.M Example 30
##STR00105## 12 .mu.M Example 31 ##STR00106## >50 .mu.M Example
32 ##STR00107## >50 .mu.M Example 33 ##STR00108## 11.5 .mu.M
Example 34 ##STR00109## >50 .mu.M Example 35 ##STR00110## >27
.mu.M Example 36 ##STR00111## 3.3 .mu.M Example SBX080 ##STR00112##
4.9 .mu.M Example SBX082 ##STR00113## 7.3 .mu.M Example SBX084
##STR00114## 3.8 .mu.M Example SBX087 ##STR00115## 1.4 .mu.M
Example SBX088 ##STR00116## 1.6 .mu.M
Other Embodiments
[0378] It is to be understood that while the invention has been
described in conjunction with the detailed description thereof, the
foregoing description is intended to illustrate and not limit the
scope of the invention, which is defined by the scope of the
appended claims. Other aspects, advantages, and modifications are
within the scope of the following claims.
* * * * *